U.S. Stem Cell (USRM) 10-K16 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Mar. 16, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	BIOHEART, INC.
Entity Central Index Key	1388319
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$10,546,291
Entity Common Stock, Shares Outstanding		647,653,526

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$36,674	$46,227
Accounts receivable, net	95,409	19,913
Prepaid and other	9,255	784
Total current assets	141,338	66,924
Property and equipment, net	12,686	9,055
Other assets
Investments	40,597
Deposits	10,160	10,160
Total assets	204,781	86,139
Current liabilities:
Accounts payable	1,991,979	2,382,267
Accrued expenses	2,373,615	4,480,335
Advances, related party	148,759	416,198
Deposits	478,286	478,286
Subordinated debt, related party	1,500,000	1,500,000
Notes payable, related party	2,333,059	2,241,477
Notes payable, net of debt discount	1,531,812	1,930,841
Derivative liabilities	741,271	403,811
Total current liabilities	11,098,781	13,833,215
Commitments and contingencies
Stockholders' deficit:
Preferred stock, par value $0.001; 20,000,000 shares authorized, 20,000,000 issued and outstanding	20,000	20,000
Common stock, par value $0.001; 2,000,000,000 and 950,000,000 shares authorized, respectively, 581,433,153 and 379,787,745 shares issued and outstanding as of December 31, 2014 and 2013, respectively	581,433	379,788
Additional paid in capital	108,939,061	103,819,119
Common stock subscription		215,000
Accumulated deficit	-120,434,494	-118,180,983
Total stockholders' deficit	-10,894,000	-13,747,076
Total liabilities and stockholders' deficit	$204,781	$86,139

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Balance Sheets [Abstract]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	20,000,000	20,000,000
Preferred stock, shares outstanding	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	2,000,000,000	950,000,000
Common stock, shares issued	581,433,153	379,787,745
Common stock, shares outstanding	581,433,153	379,787,745

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
Statements of Operations (USD $)	Dec. 31, 2014	Dec. 31, 2013
Revenue:
Products	$1,155,543	$70,396
Services	900,288	25,689
Total revenue	2,055,831	96,085
Cost and operating expenses:
Cost of sales	844,941	30,831
Research and development	66,420	626,983
Marketing, general and administrative	4,669,432	2,267,831
Depreciation and amortization	4,490	2,190
Total operating expenses	5,585,283	2,927,835
Net loss from operations	-3,529,452	-2,831,750
Other income (expenses):
Gain on settlement of debt	2,498,676	1,023,439
Gain on change of fair value of derivative liability	425,953	29,179
Loss from equity investment	-9,117
Other income		73,756
Interest expense	-1,639,571	-1,437,883
Total other income (expenses)	1,275,941	-311,509
Net loss before income taxes	-2,253,511	-3,143,259
Income taxes (benefit)
NET LOSS	($2,253,511)	($3,143,259)
Net loss per common share, basic and diluted	($0.01)	($0.01)
Weighted average number of common shares outstanding, basic and diluted	488,667,063	251,828,970

Statement_of_Stockholders_Equi

Statement of Stockholders' Equity Deficit (USD $)	Total	Preferred stock	Common stock	Additional Paid in Capital	Subscription Receivable	Accumulated Deficit
Beginning Balance at Dec. 31, 2012	($14,595,267)		$182,063	$100,260,094		($115,037,724)
Beginning Balance, Shares at Dec. 31, 2012			182,062,802
Reclassify the fair value of excess committed shares liability to equity upon common share authorization increase	474,954			474,954
Issuance of common stock	865,000		50,029	814,971
Issuance of common stock, Shares			50,029,227
Common stock issued under put agreement	346,914		31,053	315,861
Common stock issued under put agreement, Shares			31,052,141
Common stock issued in connection with issuance of convertible debt	36,250		2,500	33,750
Common stock issued in connection with issuance of convertible debt, Shares			2,500,000
Common stock issued in connection with settlement of debt	653,135		47,968	605,167
Common stock issued in connection with settlement of debt, Shares			47,967,906
Common stock issued in settlement of interest and penalty in connection with convertible debt	150,815		9,409	141,406
Common stock issued in settlement of interest and penalty in connection with convertible debt, Shares			9,408,718
Common stock issued for services	85,151		6,220	78,931
Common stock issued for services, Shares			6,220,263
Common stock issued in settlement of related party notes payable	537,750		44,890	492,860
Common stock issued in settlement of related party notes payable, Shares			44,890,348
Common stock issued in settlement of accounts payable	157,216		5,656	151,560
Common stock issued in settlement of accounts payable, Shares			5,656,340
Preferred stock issued in settlement of debt	70,000	5,000		65,000
Preferred stock issued in settlement of debt, Shares		5,000,000
Preferred stock issued in settlement of forbearance agreement	274,050	15,000		259,050
Preferred stock issued in settlement of forbearance agreement, Shares		15,000,000
Proceeds from issuance of common stock	215,000				215,000
Proceeds from issuance of common stock, Shares
Stock based compensation	125,515			125,515
Net income/ loss	-3,143,259					-3,143,259
Ending Balance at Dec. 31, 2013	-13,747,076	20,000	379,788	103,819,119	215,000	-118,180,983
Ending Balance, Shares at Dec. 31, 2013		20,000,000	379,787,745
Issuance of common stock	479,625
Issuance of common stock, Shares	42,066,606
Common stock issued for services	183,991		3,840	180,151
Common stock issued for services, Shares			3,839,832
Common stock issued in settlement of accounts payable	1,071,155		48,585	1,022,570
Common stock issued in settlement of accounts payable, Shares			48,584,542
Proceeds from issuance of common stock	479,625		42,066	652,559	-215,000
Proceeds from issuance of common stock, Shares			42,066,606
Common stock issued upon exercise of warrants	136,000		11,918	124,082
Common stock issued upon exercise of warrants, Shares			11,918,181
Common stock issued in connection with settlement of other debt	2,230,807		83,236	2,147,571
Common stock issued in connection with settlement of other debt, Shares			83,236,247
Common stock issued as commitment shares in connection with equity purchase agreement			12,000	-12,000
Common stock issued as commitment shares in connection with equity purchase agreement, Shares			12,000,000
Reclassify fair value of derivative liability to equity upon debt extinguishment	128,624			128,624
Reclassify fair value of derivative liability to equity upon debt extinguishment, Shares
Fair value of vesting warrants issued in connection with revenue sharing arrangement	190,262			190,262
Stock based compensation	686,123			686,123
Net income/ loss	-2,253,511					-2,253,511
Ending Balance at Dec. 31, 2014	($10,894,000)	$20,000	$581,433	$108,939,061		($120,434,494)
Ending Balance, Shares at Dec. 31, 2014		20,000,000	581,433,153

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
Statements of Cash Flows (USD $)	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($2,253,511)	($3,143,259)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,490	2,190
Bad debt expense	28,732
Discount on convertible debt	546,970	368,682
Gain on change in fair value of derivative liability	-425,953	-29,179
Gain on settlement of debt	-2,498,676	-1,023,439
Non-cash payment of interest	705,710	228,657
Change in fair value of warrant modifications	148,517
Warrants issued in connection with revenue share arrangement	190,262
Related party notes payable issued for services rendered	800,000	500,000
Loss on equity investments	9,117
Common stock issued in connection with accounts payable		2,500
Common stock issued in exchange for services	38,750	85,151
Preferred stock issued in settlement of debt and forbearance agreement		274,050
Stock based compensation	537,606	125,515
(Increase) decrease in:
Receivables	-104,228	-18,571
Inventory		62,953
Prepaid and other current assets	-8,471	85,251
Increase (decrease) in:
Accounts payable	858,437	-59,059
Accrued expenses	313,601	625,232
Net cash used in operating activities	-1,108,647	-1,913,326
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for investments	-49,714
Acquisitions of property and equipment	-8,121	-9,425
Net cash used by investing activities	-57,835	-9,425
CASH FLOWS FROM FINANCING ACTIVITIES:
Bank overdraft		-89
Proceeds from issuance of common stock, net	479,625	1,426,914
Proceeds from related party advances	33,760	215,500
Proceeds from exercise of stock options and warrants	136,000
Proceeds from notes payable	740,500	415,500
Repayments of notes payable	-232,956	-88,847
Net cash provided in financing activities	1,156,929	1,968,978
Net (decrease) increase in cash and cash equivalents	-9,553	46,227
Cash and cash equivalents, beginning of period	46,227
Cash and cash equivalents, end of period	36,674	46,227
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	429,569	521,742
Income taxes paid
Non cash financing activities:
Common stock issued in settlement of notes payable	1,367,927	793,135
Common stock issued in settlement of accounts payable	1,071,155	157,216
Common stock issued in settlement of related party notes and advances payable	862,880	397,750
Common stock issued in settlement of interest and penalties in connection with convertible debt		150,815
Preferred stock issued in settlement of notes payable		70,000
Reclassification of fair value of excess committed share liability to equity upon common share authorization increase		$474,954

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
Significant Accounting Policies	Dec. 31, 2014
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 — SIGNIFICANT ACCOUNTING POLICIES



	A summary of the significant accounting policies applied in the presentation of the accompanying financial statements follows:



	Basis and business presentation



	Bioheart, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Our business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. To date, the Company has not generated significant sales revenues to cover costs, incurred expenses, and as a result has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise.



	Estimates



	The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, revenues and expenses and certain disclosures. The most significant estimates are those used in determination of derivative liabilities and stock compensation. Accordingly, actual results could differ from those estimates.



	Revenue Recognition



	The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.



	At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.



	Revenues for test kits and equipment sold are not recorded until test kits are delivered. The Company has revenue sharing arrangements for the sale of goods whereby the Company is the primary obligor, sets pricing with the customers and bears all associated credit risks with the customers. Sales under revenue share arrangements are recorded as gross sales and any portion shared with third parties under such arrangements are classified as selling expense due to the nature of the marketing activities performed by the third party. Revenues from trainings are not recorded until the completion of the training. Any cash received as a deposit for trainings are recorded by the company as a liability.



	Patent treatments and laboratory services revenue are recognized when those services have been completed or satisfied.



	Revenues for bank sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets.



	Cash



	The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.



	Accounts Receivable



	Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.



Allowance for Doubtful Accounts



Any changes to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2014 and 2013, allowance for doubtful accounts was $-0-.



Long-Lived Assets



The Company follows FASB ASC 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company determined that there was no impairment on its long-lived assets during 2014 and 2013.



Property and Equipment



Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years.



Income Taxes



The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of derivative liability and stock compensation accounting versus tax differences.



Investments



The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting.



Comprehensive Income



The Company does not have any items of comprehensive income in any of the periods presented.



Net Loss per Common Share, basic and diluted



The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options and warrants have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 668,063,786 and 344,241,761 for the years ended December 31, 2014 and 2013, respectively.



Stock based compensation



The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of December 31, 2014, there were outstanding stock options to purchase 66,925,209 shares of common stock, 24,814,222 shares of which were vested.



Concentrations of Credit Risk



The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.



As of December 31, 2014, two customers represented 38% and 17%, aggregate of 55% of the Company’s accounts receivable. As of December 31, 2013, three customers represented 36%, 20% and 20%, aggregate of 76%, of the Company’s accounts receivable.



The Company’s revenues earned from sale of products and services for the year ended December 31, 2014 included 10% of the Company’s total revenues from one customer. For the year ended December 31, 2013, Company’s revenues earned from sale of products and services included 20% of the Company’s total revenues from one customer.



Reliance on Key Personnel and Consultants



The Company has three full-time employees and no part-time employees. The Company is heavily dependent on the continued active participation of its two current executive officers, one employee and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.



Research and Development



The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $66,420 and $626,983 for the years ended December 31, 2014 and 2013, respectively.



Derivative Instrument Liability



The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2014 and 2013, the Company did not have any derivative instruments that were designated as hedges.



At December 31, 2014, the Company had outstanding convertible notes that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 10)



Fair Value



Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.



Reclassification



Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.



Recent Accounting Pronouncements



In August, 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties About an Entities Ability to Continue as a Going Concern. The standard is intended to define management’s responsibility to decide whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The standard requires management to decide whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The standard provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations in the footnotes. The standard becomes effective in the annual period ending after December 15, 2016, with early application permitted. The adoption of this pronouncement is not expected to have a material impact on the consolidated financial statements. Management’s evaluations regarding the events and conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern have been disclosed in Note 2.



There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

Going_Concern_Matters

Going Concern Matters	12 Months Ended
Going Concern Matters	Dec. 31, 2014
Going Concern Matters [Abstract]
GOING CONCERN MATTERS	NOTE 2 — GOING CONCERN MATTERS



	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements during year ended December 31, 2014, the Company incurred net losses of $2,253,511 and used $1,108,647 in cash for operating activities. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.



	The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.



	The Company’s ability to obtain additional debt financing and/or alternative arrangements, with the Guarantors or otherwise, may be limited by the amount of, terms and restrictions of our then current debt. Accordingly, until such time, we will generally be restricted from, among other things, incurring additional indebtedness or liens, with limited exceptions. Additional debt financing, if available, may involve restrictive covenants that limit or further limit our operating and financial flexibility and prohibit us from making distributions to shareholders.

Investments

Investments	12 Months Ended
Investments	Dec. 31, 2014
Investments [Abstract]
INVESTMENTS	NOTE 3 — INVESTMENTS



	Investment is comprised of a 33% ownership of U.S. Stem Cell Clinic, LLC, accounted for using the equity method of accounting. The initial investment in 2014 of cash and expenses paid on U.S. Stem Cell Clinic, LLC’s behalf was in aggregate of $49,714. The Company’s 33% loss incurred by U.S. Stem Cell Clinic, LLC of $9,117 was recorded as other income/expense in the Company’s Statement of Operations for the year ended December 31, 2014 and reduced the carrying value of the investment to $40,597.

Property_and_Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2014
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 — PROPERTY AND EQUIPMENT



	Property and equipment as of December 31, 2014 and 2013 is summarized as follows:



		2014			2013
	Laboratory and medical equipment	$	352,358		$	352,358
	Furniture, fixtures and equipment		125,634			125,634
	Computer equipment		47,647			39,525
	Leasehold improvements		362,046			362,046
			887,685			879,563
	Less accumulated depreciation and amortization		(874,999	)		(870,508	)
		$	12,686		$	9,055



	Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives.



	Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment in accordance with the guidance for impairment of long lived assets.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Accrued Expenses [Abstract]
ACCRUED EXPENSES	NOTE 5 — ACCRUED EXPENSES



	Accrued expenses consisted of the following as of December 31, 2014 and 2013:



		2014		2013
	License and royalty fees	$	—	$	2,122,130
	Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,533,217		1,373,775
	Interest payable on notes payable		685,575		714,180
	Vendor accruals and other		120,836		120,692
	Employee commissions, compensation, etc.		33,987		149,558
		$	2,373,615	$	4,480,335



	During the year ended December 31, 2013, 1,000,000 shares of common stock at a common market price of $0.0195 were issued to one debt holder in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note. As a result of the settlement, the Company recognized a gain of $1,078,625 during the year ended December 31, 2013.



	In June 2000, the Company had entered into an agreement with William Beaumont Hospital, or WBH, pursuant to which WBH granted the Company a worldwide, exclusive, non-sublicenseable license to two U.S. method patents covering the inducement of human adult myocardial cell proliferation in vitro, or the WBH IP. The term of the agreement was for the life of the patents, which expire in 2015. The Company did not use this license in any of their technologies or made any payments to WBH other than the initial payment to acquire the license. On April 2, 2014, the Company received confirmation from WBH that it has no obligation under the patent license agreement and WBH agreed to terminate the patent license agreement pursuant to a termination letter dated March 3, 2014. Accordingly, the Company recognized approximately $2,122,130 in settlement of debt which represents the accumulative accrual and related interest from past years under the 2000 patent license agreement.



	During the year ended December 31, 2014, the Company issued an aggregate of 48,584,542 shares of its common stock in settlement of outstanding accounts payable and accrued expenses. In connection with the issuance, the Company incurred $120,656 net gain in settlement of debt.

Standby_Equity_Distribution_Ag

Standby Equity Distribution Agreement	12 Months Ended
Standby Equity Distribution Agreement	Dec. 31, 2014
Standby Equity Distribution Agreement [Abstract]
STANDBY EQUITY DISTRIBUTION AGREEMENT	NOTE 6 – STANDBY EQUITY DISTRIBUTION AGREEMENT



	Greystone Capital Partners



	On November 2, 2011, the Company and Greystone Capital Partners (“Greystone”) entered into a Standby Equity Distribution Agreement (the “Agreement”). Pursuant to the Agreement, Greystone has agreed to provide the Company with up to $1,000,000 of funding for the 24-month period following the date February 10, 2012, the registration statement of the Company’s common stock was declared effective by the SEC (the “Equity Line”).



	During this 24-month period, commencing on the date on which the SEC first declared the registration statement effective, the Company may request a draw down under the Equity Line by which the Company would sell shares of its common stock to Greystone, which is obligated to purchase the shares under the Agreement.



	For each share of the Company common stock purchased under the Agreement, Greystone will pay eighty percent (80%) of the average of the lowest daily volume weighted average price for five consecutive trading days immediately preceding Advance Notice (the “Valuation Period”) commencing the date an Advance Notice (the “Advance Notice”) is delivered to Greystone in a manner provided by the Agreement. Subject to certain limitations and floor price reductions, the Company may, at its sole discretion, issue a Put Notice to Greystone and Greystone will then be irrevocably bound to acquire such shares. The registration statement of the Company’s common stock pursuant to the Agreement was declared effective on February 10, 2012 and a Post-Effective Amendment was declared effective on May 7, 2013. On December 1, 2012, the parties to the Equity Line agreed that the Purchase Price be adjusted to seventy-five percent (75%) of the lowest daily volume weighted average price of the Common Stock as quoted by Bloomberg, LP, during the five (5) consecutive Trading Days (as such term is defined in the Equity Line) immediately subsequent to the date of the relevant Advance Notice.



	During the year ended December 31, 2013, the Company issued an aggregate of 31,052,141 shares of its common stock in exchange for $346,914 draw down on the equity line.



	The Agreement automatically terminated on the first of April, 2014 (the first day of the month next following the second (2^nd) anniversary of the Effective Date).

Stock_Purchase_Agreement

Stock Purchase Agreement	12 Months Ended
Stock Purchase Agreement	Dec. 31, 2014
Stock Purchase Agreement [Abstract]
STOCK PURCHASE AGREEMENT	NOTE 7 – STOCK PURCHASE AGREEMENT



	On October 23, 2014, the Company, entered into a common stock purchase agreement (the “Purchase Agreement”) with Magna Equities II, LLC, a New York limited liability company (the “Investor”). The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, the Investor is committed to purchase up to $3,000,000 (the “Total Commitment”) worth of the Company’s common stock, $0.001 par value (the “Shares”), over the 24-month term of the Purchase Agreement.



	From time to time over the term of the Purchase Agreement, commencing on the trading day immediately following the date on which the initial registration statement is declared effective by the Securities and Exchange Commission (the “Commission”), the Company may provide the Investor with a draw down notice to purchase a specified dollar amount of Shares, with each draw down subject to certain limitations. The Company may not deliver any Draw Down Notice to the Investor if the Initial Purchase Price with respect to the Shares subject to such Draw Down Notice is less than $0.0025 as of the date the applicable Draw Down Notice is received by the Investor (the “Draw Down Exercise Date”).



	The applicable Initial Purchase Price. The “Initial Purchase Price” is defined as a price equal to 93% of the lowest of (i) the arithmetic average of the three lowest daily volume weighted average prices for the Company’s common stock (the “VWAP”) during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date, (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date and (iii) the closing sale price for the Company’s common stock on the trading day immediately preceding the applicable Draw Down Exercise Date.



	The Company paid to the Investor as a commitment fee for entering into the Purchase Agreement equal an aggregate of to 12,000,000 shares of the Company’s common stock.

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 8 — NOTES PAYABLE



	Notes payable were comprised of the following as of December 31, 2014 and 2013:



		2014			2013
	Seaside Bank note payable.	$	980,000		$	980,000
	August 2008 Unsecured Promissory Note		—			500,000
	Hunton & Williams notes payable		384,972			384,972
	Asher notes payable		151,000			143,000
	Daniel James Management note payable		75,000			—
	Fourth Man, LLC note payable		75,000			35,000
	Magna Group		205,000			—
	Total notes payable		1,870,972			2,042,972
	Less unamortized debt discount		(339,160	)		(112,131	)
	Total notes payable net of unamortized debt discount	$	1,531,812		$	1,930,841



	Seaside Bank



	On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2014 to extend the maturity date to December 23, 2015.



	August 2008 Unsecured Promissory Note



	On August 20, 2008, the Company borrowed $1.0 million from a third party pursuant to the terms of an unsecured Promissory Note and Agreement. Outstanding principal and interest on the loan, which accrues at the rate of 13.5% per annum, would be payable in one balloon payment upon the Company’s repayment of the BlueCrest Loan, which was scheduled to mature in May 2010, however the Company was not obligated to make payments until BlueCrest Loan is paid off.



	In the event the Company completes a private placement of its common stock and/or securities exercisable for or convertible into its common stock which generates at least $19.0 million of gross proceeds, the Company may prepay, without penalty, all outstanding principal and interest due under the loan using the same type of securities issued in the subject private placement. Because repayment of the loan could occur within 12 months from the date of the balance sheet, the Company has classified this loan as short term.



	Subject to certain conditions, at the end of each calendar quarter during the time the loan is outstanding, the Company may, but is not required to, pay all or any portion of the interest accrued but unpaid as of such date with shares of its common stock. In April 2009, as consideration for the authorization to amend certain documents related to the Note, the Company issued to the Note holder a warrant to purchase 451,053 shares of common stock at an exercise price of $0.5321 per share. The warrant, which became exercisable immediately upon issuance, has a ten year term. This warrant had a fair value of $195,694, which was accounted for as additional paid in capital and reflected as a component of debt discount and has been fully amortized as interest expense ratably over the term of the loan.



	In 2013, 1,000,000 shares of common stock were issued to the debt holder, in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note resulting in a gain of $1,078,625. A gain of $1,078,625 was included in the net gain on settlement of debt and trade payables on the statement of operations for the year ended December 31, 2013.



	On June 16, 2014, 14,539,191 shares of common stock were issued to the debt holder, in exchange for the remaining $500,000 principal and $81,568 of accrued interest resulting in a gain of $255,890. A gain of $255,890 was included in the net gain on settlement of debt and trade payable on the statement of operations for the year ended December 31, 2014.



	Hunton & Williams Notes



	At December 31, 2014 and 2013, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822, are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.



	Asher Notes



2013 Notes



During the year ended December 31, 2013, the Company entered into a Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”), for the sale of 8% convertible notes in aggregate principal amount of $255,500 (the “Asher Notes”).



The Asher Notes bear interest at the rate of 8% per annum. As of the December 31, 2013 all interest and principal must be repaid nine months from the issuance date, the last note due August 7, 2014. The Notes are convertible into common stock, at Asher’s option, at a 42% to 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes. These embedded derivatives included certain conversion features and reset provision.



The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date. At the inception of the Asher Notes, the Company determined the aggregate fair value of $335,089 of the embedded derivatives.



The fair value of the embedded derivatives was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 154.80% to 164.29%, (3) weighted average risk-free interest rate of 0.09% to 0.17%, (4) expected lives of 0.67 to .77 years, and (5) estimated fair value of the Company’s common stock from $0.01 to $0.0373 per share. The initial fair value of the embedded debt derivative of $335,089 was allocated as a debt discount up to the proceeds of the note ($255,500) with the remainder ($79,589) charged to current period operations as interest expense. For the years ended December 31, 2014 and 2013, the Company amortized $92,794 and $162,706 of debt discount to current period operations as interest expense, respectively. As of December 31, 2014 the gross balance of the 2013 Asher Notes was $-0-.



2014 Notes



During the year ended December 31, 2014, the Company entered into a Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”) or affiliates, for the sale of 8% convertible notes in aggregate principal amount of $334,000 (the “Asher Notes”).



The Asher Notes bear interest at the rate of 8% per annum. As of December 31, 2014, all interest and principal must be repaid nine months from the issuance date, with the last note being due August 12, 2015. The Notes are convertible into common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes.



These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date, which at December 31, 2014 was $149,770. At the inception of the Asher Notes, the Company determined the aggregate fair value of $566,294 of the embedded derivatives.



For the year ended December 31, 2014, the Company amortized $248,153 of debt discount to current period operations as interest expense.



The remaining principle balance as of December 31, 2014 was $151,000.



Fourth Man, LLC



2013 Notes



On October 11, 2013, the Company entered into a Securities Purchase Agreement with Fourth Man, LLC. (“Fourth Man”), for the sale of an 8% convertible note in the principal amount of $35,000 (the “Note”).



The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on April 10, 2014. The Note is convertible into common stock, at Fourth Man’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Fourth Man Note. These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Fourth Man Note and to fair value as of each subsequent reporting date. At the inception of the Fourth Man Note, the Company determined the aggregate fair value of $52,894 of the embedded derivatives.



The fair value of the embedded derivatives was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 164.29%, (3) weighted average risk-free interest rate of 0.07%, (4) expected life of 0.50 year, and (5) estimated fair value of the Company’s common stock of $0.0121 per share. The initial fair value of the embedded debt derivative of $52,894 was allocated as a debt discount up to the proceeds of the note ($35,000) with the remainder ($17,894) charged to current period operations as interest expense. For the years ended December 31, 2014 and 2013, the Company amortized $19,337 and $15,663 of debt discount to current period operations as interest expense, respectively.



2014 Notes



During the year ended December 31, 2014, the Company entered into Securities Purchase Agreements with Fourth Man, LLC. (“Fourth Man”), for the sale of an 8% to 9.5% convertible notes in the aggregate principal amount of $100,000 (the “Note”).



The Notes bears interest at the rate of 8% to 9.5% per annum. As of the year ended December 31, 2014, all interest and principal must be repaid one year from the issuance date, with the last note being due August 28, 2015. The Notes are convertible into common stock, at Fourth Man’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Fourth Man Notes. These embedded derivatives included certain conversion features and reset provision.



The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Fourth Man Notes and to fair value as of each subsequent reporting date which at December 31, 2014 was $93,505. At the inception of the Fourth Man Notes, the Company determined the aggregate fair value of $168,501 of the embedded derivatives.



For the year ended December 31, 2014, the Company amortized $50,549 of debt discount to current period operations as interest expense.



The remaining principle balance as of December 31, 2014 was $75,000.



Daniel James Management



2014 Notes



During the year ended December 31, 2014, the Company entered into Securities Purchase Agreements with Daniel James Management (“Daniel”) for the sale of 8% to 9.5% convertible notes in aggregate principal amount of $135,000 (the “Daniel Notes”).



The Daniel Notes bear interest at the rate of 8% to 9.5% per annum. As of the year ended December 31, 2014, all interest and principal must be repaid one year from the issuance date, with the last note being due November 30, 2015. The Daniel Notes are convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Daniel Note. These embedded derivatives included certain conversion features and reset provision.



The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Daniel Notes and to fair value as of each subsequent reporting date which at December 31, 2014 was $95,866. At the inception of the Daniel Notes, the Company determined the aggregate fair value of $236,211 of the embedded derivatives.



For the year ended December 31, 2014, the Company amortized $76,758 of debt discount to current period operations as interest expense.

The remaining principle balance as of December 31, 2014 was $75,000.



Magna Capital Group



2014 Notes



During the year ended December 31, 2014, the Company entered into a Securities Purchase Agreement with Magna Capital Group (“Magna”) for the sale of a convertible note in aggregate principal amount of $307,500 (the “Magna Note”) and an original interest discount (“OID”) of $102,500. $40,000 of the outstanding principal amount of the Convertible Note (together with any accrued and unpaid interest with respect to such portion of the principal amount) will be automatically extinguished upon the filing of the registration statement, following the closing of the Securities Purchase Agreement. In addition, $62,500 of the outstanding principal amount of the Convertible Note (together with any accrued and unpaid interest with respect to such portion of the principal amount) will be automatically extinguished if (i) the registration statement is declared effective by the SEC on or prior to the earlier of (A) the 120^th calendar day after October 7, 2014 and (B) the fifth business day after the date we are notified by the Securities and Exchange Commission, or the Commission, that the registration statement will not be reviewed or will not be subject to further review, and this prospectus is available for use by Magna for the resale by Magna of all of the shares of our common stock issued or issuable upon conversion of the Convertible Note and (ii) no event of default under the Convertible Note or an event that with the passage of time or giving of notice would constitute an event of default under the Convertible Note has occurred on or prior to such date. On November 21, 2014, the Company filed its registration statement and on December 22, 2014, was declared effective. As such, the principle amount of the note was reduced by an aggregate of $102,500.



The Convertible Note matures on August 7, 2015 and, in addition to the approximately 33.33% original issue discount, accrues interest at the rate of 12% per year. The Convertible Note is convertible at any time, in whole or in part, at Magna’s option into shares of Company common stock at a fixed conversion price of $0.01035 per share, subject to adjustment pursuant to the “full ratchet” and standard anti-dilution provisions contained in the Convertible Note. This resulted in an embedded derivatives liability as a result of these anti-dilution provision. This conversion price represents a discount of approximately 45% from the lowest trading price the Company common stock during the five trading days prior to October 7, 2014, the date the Company issued the Convertible Note to Magna.



The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivative as of the inception date of Magna Note and to fair value as of each subsequent reporting date which at December 31, 2014 was $252,211. At the inception of the Magna Note, the Company determined the aggregate fair value of $472,702 of the embedded derivative. At the dates of debt reductions, as described above, the Company reclassified the fair value of the related derivative liability of $128,624 to additional paid in capital.



For the year ended December 31, 2014, the Company amortized $57,319 of debt discount to current period operations as interest expense.



The remaining principle balance as of December 31, 2014 was $205,000.



For 2013, the fair value of the embedded derivatives was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 154.80% to 164.29%, (3) weighted average risk-free interest rate of 0.07% to 0.17%, (4) expected lives of 0.50 to .77 years, and (5) estimated fair value of the Company’s common stock from $0.01 to $0.0373 per share. The initial fair value of the embedded debt derivative of $387,983 was allocated as a debt discount up to the proceeds of the note ($290,500) with the remainder ($97,483) charged to current period operations as interest expense.



For 2014, the fair value of the embedded derivatives were determined using the Binomial Option Pricing Model based on the following assumptions at December 31, 2014: (1) dividend yield of 0%, (2) expected volatility of 146.33% to 171.91%, (3) weighted average risk-free interest rate of 0.10% to 0.25%, (4) expected lives of 0.76 to 1.00 years, and (5) estimated fair value of the Company’s common stock from $0.0105 to $0.0486 per share. The initial fair value of the embedded debt derivative of $1,443,708 was allocated as a debt discount up to the proceeds of the notes ($768,000) with the remainder ($675,708) charged to current period operations as interest expense. For the years ended December 31, 2014 and 2013, the Company amortized an aggregate of $575,629 and $368,682 of debt discounts to current period operations as interest expense, respectively.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 — RELATED PARTY TRANSACTIONS



	Advances



	As of December 31, 2014 and 2013, the Company officers and directors have provided advances in the aggregate of $148,759 and $416,198 respectively, for working capital purposes. The advances are unsecured, due on demand and non-interest bearing.



	On August 1, 2013, advances in aggregate of $22,750 were converted into a demand promissory note with 5% interest per annum. On September 30, 2013, the Company issued 1,995,614 shares of common stock in settlement of the $22,750 promissory note.



	On September 30, 2013, the Company issued 8,771,929 shares of its common stock as payment of $100,000 towards cash advances.



	During the year ended December 31, 2014, the Company issued an aggregate of 10,232,286 shares of common stock in settlement of $298,759 of related party advances and outstanding accounts payable.



	Notes payable-related party



	Northstar Biotechnology Group, LLC



	On February 29, 2012, a note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267.



	On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.



	On September 21, 2012, the Company issued 5,000,000 common stock purchase warrants to Northstar that was treated as additional interest expense upon issuance.



	On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.



	In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.



	Effective October 1, 2012, the effective interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum.



	In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement.



	In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued, which was subsequently increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. In addition, the Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock. The Company is required to issue additional shares of its common stock (as amended), in lieu of cash, each six month anniversary of the effective date for any accrued and unpaid interest.



As described above, during the year ended December 31, 2013, the Company issued the 5,000,000 shares of Series A Convertible Preferred Stock and the 10,000,000 of common stock described above in exchange for the $210,000 as payment towards outstanding principle of the debt. In addition, the Company issued 15,000,000 shares of Series A Convertible Preferred Stock as a penalty in settlement of the terms of the forbearance agreement. The fair value of the Preferred Stock of $274,050 was included in interest expense for the year ended December 31, 2013.



On September 30, 2013, the Company issued 8,771,929 shares of its common stock as payment of $100,000 towards cash advances.



On December 24, 2013, the Company issued 3,915,662 shares of its common stock as payment of accrued interest through June 30, 2013 of $85,447.



On April 2, 2014, the Company issued 274,681 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2014 per the forbearance agreement.



On September 17, 2014, limited waiver and forbearance agreement entered into on October 1, 2012 to provide that the perpetual license on products as described for resale, relicensing and commercialization outside the United States was amended as such to condition upon NorthStar providing certain financing, which financing the Company, in its sole discretion, could decline and retain the license.



On October 3, 2014, the Company issued 514,886 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2014 per the forbearance agreement.



As of December 31, 2014 and 2013, the principle of this note was $362,000.



Officer and Director Notes



	2014		2013
Notes payable, Dr Murphy	$	465,240	$	763,626
Note payable, Dr. Ahn		-		125,000
Note payable, Mr. Tomas		331,354		518,133
Note payable, Mr. Tomas		375,000		375,000
Note payable, Mr. Tomas		500,000		-
Note payable, Ms. Comella		-		97,718
Note payable, Ms. Comella		299,465		-
Total	$	1,971,059	$	1,879,477



Notes payable, Dr. Murphy



At December 31, 2014 and 2013, the Company has outstanding notes payable to Dr. Murphy with interest at 8% per annum due at maturity in aggregate $465,240 and $763,626, respectively. Of the outstanding balance, certain subordinated notes $100,000 and $140,000 were previously due on November 30, 2012 and June 4, 2011 respectively, and are unsecured. The Company is not obligated to make payment until Northstar loan is paid off.



On June 20, 2014, the Company issued 10,333,475 shares of its common stock in settlement of $298,386 of related party note payable, $2,000 advances and accrued interest of $112,954.



Note payable, Dr. Ahn



At December 31, 2013, the Company has outstanding note payable for $125,000 to Dr. Ahn with interest at 8% per annum due at maturity.



On June 20, 2014, the Company issued 4,045,796 shares of its common stock in settlement of $125,000 of related party note payable and accrued interest of $36,832.



Notes payable, Mr. Tomas



In 2013, the Company issued a promissory note payable for previous advances and accrued compensation. The promissory note bear interest of 5% per annum and due on demand. During the year ended December 31, 2014, the Company paid off $186,779 of the outstanding promissory note. The principle outstanding balance of these notes as of December 31, 2014 is $331,354.



On August 1, 2013, the Company issued a $375,000 promissory notes due on demand in settlement of accrued compensation. The promissory note bear interest of 5% per annum and due on demand. The principle outstanding balance of these notes as of December 31, 2014 is $375,000.



On July 1, 2014, the Company issued a $500,000 promissory note in settlement of accrued compensation. The promissory notes bear interest of 5% per annum and due on January 1, 2015. The principle outstanding balance of these notes as of December 31, 2014 is $375,000.



Notes payable, Ms. Comella



On August 1, 2013, the Company issued a $125,000 promissory notes due on demand in settlement of accrued compensation. The promissory note bear interest of 5% per annum and due on demand. During the year ended December 31, 2014 and 2013, the Company paid off $97,718 and $27,282 of the outstanding promissory note. The principle outstanding balance of these notes as of December 31, 2014 is $-0-.



On July 1, 2014, the Company issued a $300,000 promissory note in settlement of accrued compensation. The promissory notes bear interest of 5% per annum and due on January 1, 2015. During the year ended December 31, 2014, the Company paid off $535 of the outstanding promissory note. The principle outstanding balance of these notes as of December 31, 2014 is $299,465.



Subordinated debt, related party



As of December 31, 2014 and 2013, the Company officers and directors have provided notes in aggregate of $1,500,000. The notes range from 4.75% to 8% per annum and are due upon payoff of the Northstar note payable described above.

Derivative_Liabilities

Derivative Liabilities	12 Months Ended
Derivative Liabilities	Dec. 31, 2014
Derivative Liabilities [Abstract]
DERIVATIVE LIABILITIES	NOTE 10 — DERIVATIVE LIABILITIES



	Excessive committed shares



	On December 31, 2012, in connection with the previously issued stock options and warrants, the Company had the possibility of exceeding their common shares authorized when considering the number of possible shares that may be issuable to satisfy settlement provisions of these agreements after consideration of all existing instruments that could be settled in shares. The accounting treatment of derivative financial instruments required that the Company reclassify the derivative from equity to a liability at their fair values as of the date possible issuable shares exceeded the authorized level and at fair value as of each subsequent balance sheet date. Any change in fair value was recorded as non-operating, non-cash income or expense at each reporting date. If the fair value of the derivatives was higher at the subsequent balance sheet date, the Company recorded a non-operating, non-cash charge. If the fair value of the derivatives was lower at the subsequent balance sheet date, the Company recorded non-operating, non-cash income.



	On February 4, 2013, in conjunction with the increase in authorized number of shares to 970,000,000, the Company determined it had adequate authorized shares to settle all of these agreements. As such, the Company adjusted the derivative liability to fair value on February 4, 2013 and reclassified the derivative liability to equity. The fair value of the derivative liability of $474,954 (a non-cash item) as of February 4, 2013 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 156.52%; risk free rate: 0.38%; and expected life: 3.5 years. The Company recorded a loss on change in derivative liabilities of $84,907 during the year ended December 31, 2013.


	Reset warrants



	On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 8 above, the Company issued an aggregate of 15,000,000 common stock purchase warrants to purchase the Company’s common stock with an exercise price of $0.014 per share for ten years with anti-dilutive (reset) provisions.



	The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date.



	At December 31, 2014, the fair value of the reset provision related to the embedded derivative liability of $149,920 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 146.33%; risk free rate: 1.97%; and expected life: 7.75 years. The Company recorded a loss on change in derivative liabilities of $3,064 during the year ended December 31, 2014.



	Convertible notes



	During the year ended December 31, 2014 and 2013, the Company issued convertible notes (see Note 7 above).



	These notes are convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these notes relating to certain anti-dilutive (reset) provisions. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of these notes and to fair value as of each subsequent reporting date.



	The fair value of the embedded derivatives at December 31, 2014, in the amount of $591,351, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 146.33%, (3) weighted average risk-free interest rate of 0.04 to 0.25%, (4) expected lives of 0.24 to 0.92 years, and (5) estimated fair value of the Company’s common stock of $0.01 per share. The Company recorded a gain on change in derivative liabilities of $429,018 during the year ended December 31, 2014.



	Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2014
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 11 — STOCKHOLDERS’ EQUITY



	Preferred stock



	On August 17, 2012, the Board of Directors designated 5,000,000 shares of preferred stock as Series A Convertible Preferred Stock which was increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock (currently held by Northstar Biotechnology Group, LLC). Each share of preferred stock is convertible into equal number of common shares at the option of the holder; entitled to 20 votes on all matters presented to be voted by the holders of common stock; upon event of liquidation, entitled to amount equal to stated value plus any accrued and unpaid dividends or other fees before distribution to junior securities. In lieu of the initial two payments due to Northstar on April 1, 2013 and October 1, 2013, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders (see Note 8 above).



	During the year ended December 31, 2013, the Company issued an aggregate of 20,000,000 shares of Series A Convertible Preferred Stock for principle payment and settlement of forbearance (see note 9 above).



	Common stock



	Effective May 19, 2014, the Company amended its articles of incorporation to increase the authorized shares of capital stock of the Company from nine hundred and fifty million (950,000,000) shares of common stock and twenty million (20,000,000) shares of preferred stock, both $.001 par value respectively, to two billion (2,000,000,000) shares of shares of common stock and twenty million (20,000,000) shares of preferred stock, both $.001 par value respectively.



	During the year ended December 31, 2014, the Company issued 42,066,606 shares of common stock for proceeds of $479,625.



	During the year ended December 31, 2014, the Company issued an aggregate of 48,584,542 shares of its common stock in settlement of outstanding accounts payable and accrued expenses. In connection with the issuance, the Company incurred $57,025 loss in settlement of debt.



	During the year ended December 31, 2014, the Company issued an aggregate of 83,236,247 shares of its common stock for the conversion of $2,057,280 of notes payable and related accrued interest. In connection with the issuance, the Company incurred $255,890 gain in settlement of debt.



	During the year ended December 31, 2014, the Company issued an aggregate of 3,839,832 shares of its common stock for services provided to the Company valued at $183,991.



	During the year ended December 31, 2014, the Company issued an aggregate of 11,918,181 shares of its common stock in connection with the exercise of warrants.



	During the year ended December 31, 2014 the Company issued Magna Group 12,000,000 shares of its common stock as a commitment fee for entering into the Purchase Agreement (See Note 7).



	During the year ended December 31, 2013, the Company issued 50,029,227 shares of common stock for proceeds of $865,000.



	During the year ended December 31, 2013, the Company issued 31,052,141 shares of common stock issued under its standby equity distribution agreement with Greystone Capital Partners.



	During the year ended December 31, 2013, the Company issued an aggregate of 5,656,340 shares of its common stock for settlement of $82,339 of accounts payable. In connection with the settlement, the Company recorded a loss on settlement of debt of $74,877.



	During the year ended December 31, 2013, the Company issued 2,500,000 shares of its common stock in connection with the issuance of a note payable.



During the year ended December 31, 2013, the Company issued 57,967,906 shares of its common stock in connection with the settlement and/or conversion of various notes payable.



During the year ended December 31, 2013, the Company issued 34,890,348 shares of its common stock in connection with the settlement of related party notes payable and advances.



During the year ended December 31, 2013, the Company issued 9,408,718 shares of its common stock in settlement of interest and penalty in connection with convertible debt.



During the year ended December 31, 2013, the Company issued 6,220,263 shares of its common stock services rendered valued at $85,151.

Stock_Options_and_Warrants

Stock Options and Warrants	12 Months Ended
Stock Options and Warrants	Dec. 31, 2014
Stock Options and Warrants [Abstract]
STOCK OPTIONS AND WARRANTS	NOTE 12 — STOCK OPTIONS AND WARRANTS



	Stock Options



	In December 1999, the Board of Directors and shareholders adopted the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011.



	On April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty million shares of common stock for issuance. On August 4, 2014, the Board of Directors approved to set the reserve to one hundred million shares of common stock for issuance and to close the 1999 Officers and Employees Stock Option Plan.



	A summary of options at December 31, 2014 and activity during the nine months then ended is presented below:



			Shares				Weighted-		Weighted-
							Average		Average
							Exercise Price		Remaining
									Contractual
									Term (in years)

	Options outstanding at January 1, 2013			7,853,376			$	0.67	8.2
	Granted			17,400,000			$	0.016	9.9
	Exercised			—			$
	Forfeited/Expired			(1,340,433	)		$	1.08
	Options outstanding at December 31, 2013			23,912,943			$	0.15	9
	Granted			43,148,487			$	0.023	10
	Exercised			—
	Forfeited/Expired			(136,221	)		$	5.2
	Options outstanding at December 31, 2014			66,925,209			$	0.056	8.9
	Options exercisable at December 31, 2014			24,814,222			$	0.12	8.7
	Available for grant at December 31, 2014			96,500,000



	The following information applies to options outstanding and exercisable at December 31, 2014:



			Options Outstanding						Options Exercisable
			Shares		Weighted-		Weighted-		Shares		Weighted-
					Average		Average				Average
					Remaining		Exercise				Exercise
					Contractual		Price				Price
					Term

	$0.00 – $0.70		66,438,487		9		$	0.03	24,327,500		$	0.03
	$0.71 – $1.28		149,930		3.8		$	0.81	149,930		$	0.81
	$5.25 – $5.67		312,080		1.6		$	5.53	312,080		$	5.53
	$7.69		24,712		1.6		$	7.69	24,712		$	7.69
			66,925,209		8.9		$	0.056	24,814,222		$	0.12



	On August 5, 2013, the Company re-priced options previously issued from 2011 through 2012 for current employees and officers in aggregate of 4,890,000 options with previous exercise prices from $0.03 to $0.21 per share to $0.01694 per share, all other terms remaining unchanged. The gross change in fair value, determined using the Black Scholes option pricing model, of $1,630 was charged to operations.



	On August 1, 2013, the Company issued an aggregate 15,000,000 options to purchase the Company’s common stock at $0.01576 per share to employees, exercisable over 4 years. The fair value of $245,749, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 153.27% and Risk free rate: 2.74%, of which $25,599 was charged to operations.



On September 1, 2013, the Company issued an aggregate 2,400,000 options to purchase the Company’s common stock at $0.01654 per share, respectively; to officers and employees, exercisable immediately. The fair value of $37,823, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 150.98% and Risk free rate: 2.78%, was charged to operations.



On February 24, 2014, the Company issued an aggregate 15,000,000 options to purchase the Company’s common stock at $0.019 per share to officers, vesting at 25% immediately and the remainder over approximately 42 months, exercisable over 10 years. The aggregate fair value of $282,597, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 163.63% and Risk free rate: 2.75%.



On February 24, 2014, the Company issued an aggregate 4,800,000 options to purchase the Company’s common stock at $0.019 per share to officers, vesting immediately and exercisable over 10 years. The aggregate fair value of $90,431, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 163.63% and Risk free rate: 2.75%.



On May 12, 2014, the Company issued an aggregate 4,848,487 options to purchase the Company’s common stock at $0.0272 per share to officers and employees, vesting over four years at anniversary and exercisable over 10 years. The aggregate fair value of $130,135, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 161.36% and Risk free rate: 2.66%.



On August 1, 2014, the Company issued an aggregate 15,000,000 options to purchase the Company’s common stock at $0.02694 per share to officers and employees, vesting at 25% immediately and 75% over three years at anniversary and exercisable over 10 years. The aggregate fair value of $391,798, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 168.62% and Risk free rate: 2.52%.

On November 3, 2014, the Company issued an aggregate 700,000 options to purchase the Company’s common stock at $0.01932 per share to officers and employees, vesting at 25% each year over four years at anniversary and exercisable over 10 years. The aggregate fair value of $12,739, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 152.87% and Risk free rate: 2.36%.



On November 3, 2014, the Company issued an aggregate 2,800,000 options to purchase the Company’s common stock at $0.01932 per share to board of directors, vesting immediately and exercisable over 10 years. The aggregate fair value of $54,957, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 152.87% and Risk free rate: 2.36%.



The fair value of all options vesting during the year ended December 31, 2014 and 2013 of $537,606 and $125,515, respectively, was charged to current period operations.



Warrants



A summary of common stock purchase warrants at December 31, 2014 and activity during the year then ended is presented below:



		Shares				Weighted-			Weighted-
						Average			Average
						Exercise			Remaining
						Price			Contractual
									Term (in years)

Outstanding at January 1, 2013			74,073,322			$	0.37			4.5
Issued			50,350,536			$	0.16			9.2
Exercised			—			$	0
Forfeited			(6,345,002	)		$	0.38
Outstanding at December 31, 2013			118,078,856			$	0.22			6.3
Issued			57,582,469			$	0.02			8.2
Exercised			(11,918,181	)		$	0.01
Expired			(13,178,145	)		$	0.08
Outstanding at December 31, 2014			150,564,999			$	0.17			6.6
Exercisable at December 31, 2014			131,822,688			$	0.1			6.7



The following information applies to common stock purchase warrants outstanding and exercisable at December 31, 2014:

		Warrants Outstanding											Warrants Exercisable
			Shares				Weighted-			Weighted-				Shares		Weighted-
							Average			Average						Average
							Remaining			Exercise						Exercise
							Contractual			Price						Price
							Term

$0.01 – $0.50			144,315,866				6.7		$	0.02				127,118,005	$	0.02
$0.52 – $0.68			2,699,675				4.3		$	0.58				2,699,675	$	0.58
$0.70 – $1.62			848,176				5		$	0.71				848,176	$	0.71
$5.67 – $7.69			2,701,282				7.9		$	7.55				1,156,832	$	7.35
			150,564,999				6.6		$	0.17				131,822,688	$	0.1



In conjunction with the authorized issuance of common stock, the Company granted approximately 50 million common stock purchase warrants during the year ended December 31, 2013.



In conjunction with the authorized issuance of common stock, the Company granted 41,582,469 common stock purchase warrants during the year ended December 31, 2014.



During the year ended December 31, 2014, the Company issued an aggregate of 8,000,000 warrants in connection with a revenue share venture agreement dated March 10, 2014. The warrants are exercisable at $0.0217 for four years vesting from June 8, 2014 through March 10, 2016 (term of agreement). During the year ended December 31, 2014, the Company charged $103,238 to current period operations.



During the year ended December 31, 2014, the Company issued an aggregate of 4,000,000 warrants in connection with use of certain intellectual property. The warrants are exercisable at $0.0481 for four years vesting from July 6, 2014 through April 6, 2017. During the year ended December 31, 2014, the Company charged $32,878 to current period operations for the vesting portion.



During the year ended December 31, 2014, the Company issued an aggregate of 4,000,000 warrants in connection with the termination of a revenue share agreement. The warrants are exercisable at $0.0157 for four years vesting May 27, 2015. During the year ended December 31, 2014, the Company charged $54,146 to current period operations.



On November 3, 2014, the Company extended an aggregate of 13,063,530 expiring warrants previously issued to the Company’s board of directors for additional three years. The aggregate change in fair value of $148,517, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 152.87% and Risk free rate: 0.96% was charged to current period operations.

Commiments_and_Contingencies

Commiments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 13 — COMMITMENTS AND CONTINGENCIES



	Leases



	The Company entered into several operating lease agreements for facilities and equipment. Terms of certain lease arrangements include renewal options, escalation clauses, payment of executory costs such as real estate taxes, insurance and common area maintenance. The landlord has filed a security interest against the assets of the Company.



	In July 2013, the Company amended its facility lease to extend the term of the lease until July 31, 2016. Approximate annual future minimum lease obligations under non-cancelable operating lease agreements as of December 31, 2014 are as follows:



	Year ending December 31,
	2015	$	86,382
	2016		43,830
	Total	$	130,212



	Rent expense was $128,136 and $123,216 for the years ended December 31, 2014 and 2013, respectively.



	Revenue Share Agreement



	On March 10, 2014, the Company entered into a revenue sharing agreement (the Agreement) with Global Stem Cells, Group, LLC and its subsidiaries whereby both parties will participate in marketing for obtaining patients and provide physician training for stem cell treatments under the names of “Regenestem” and “Stem Cell Training”, respectively. In addition, each party will be responsible for selling equipment and kit to existing and previous customers. Profits are divided on a fifty/fifty basis with distribution within 10 days of the accounting for patients and physician training and 30 day with sales of equipment and kits. In November 2014, the Company terminated the joint venture.



	In consideration of Global Stem Cell Group, LLC’s participation, the Company issued an aggregate of 8,000,000 warrants to purchase the Company’s common stock for four years at $0.0217 per share with 2,000,000 warrants vesting 90 days from the effective date, 2,000,000 vesting on each anniversary date for three years. At termination of the revenue share agreement, the Company issued an aggregate of 4,000,000 warrants to purchase the Company’s common stock. During the year ended December 31, 2014, the Company charged $54,146 to current period operations. Because of the termination of the agreement during 2014, all services were considered final and rendered and the fair value of all 12,000,000 warrants issued under this agreement were recognized during 2014.



	William Beaumont Hospital



	In June 2000, the Company entered into an agreement with William Beaumont Hospital, or WBH, pursuant to which WBH granted to the Company worldwide, exclusive, non-sublicenseable license to two U.S. method patents covering the inducement of human adult myocardial cell proliferation in vitro, or the WBH IP. The term of the agreement is for the life of the patents, which expire in 2015. The Company did not use this license in any of our technologies. The Company had not made any payments to WBH other than the initial payment to acquire the license. The Company has received confirmation from WBH that it has no obligation under the patent license agreement and WBH agreed to terminate the patent license agreement. (See Note 5)



	Accordingly, the Company has recognized approximately $2,122,130 in settlement of debt which represents the accumulative accrual and related interest from past years under the 2000 patent license agreement.

	Employment agreements



	On July 28, 2014, the Company’s Board of Directors approved the 2014/2015 salary for Mike Tomas, Chief Executive Officer, at $525,000 per year, beginning July 1, 2014 with an incentive bonus ranging from $150,000 to $500,000. In addition, the Board of Directors will grant Mr. Tomas options to be determined on or before June 30, 2015. The Company’s Board of Directors approved a bonus of $500,000 and options to acquire 10,000,000 shares of the Company’s common stock for ten years with four year vesting and a cashless exercise provision at an exercise price equal to the five day average closing price of the Company’s common stock as of August 1, 2014. The cash bonus may be paid in the form a six month promissory note.



	On July 28, 2014, the Company’s Board of Directors approved the 2014/2015 salary for Kristin Comella, Chief Scientific Officer, at $250,000 per year, beginning July 1, 2014 with an incentive bonus ranging from $100,000 to $300,000. In addition, the Board of Directors will grant Ms. Comella options to be determined on or before June 30, 2015. The Company’s Board of Directors approved a bonus of $300,000 and options to acquire 5,000,000 shares of the Company’s common stock for ten years with four year vesting and a cashless exercise provision at an exercise price equal to the five day average closing price of the Company’s common stock as of August 1, 2014. The cash bonus may be paid in the form a six month promissory note.



	Consulting agreements



On November 20, 2013, the Company entered into an investment banking agreement with Cassel Salpeter & Co. (“CSC”), who will act as exclusive third party financial advisor in connection with investment banking matters. The term of the Investment Banking Agreement shall be for a period of twenty four months unless terminated or extended in accordance with its terms. For these services, CSC will receive a one-time $25,000 fee, $5,000 monthly fees and 5,207,630 ten year common stock purchase warrants, exercisable at $.0113 and applicable consideration in the event the closing of a Mezzanine Financing consisting of non-convertible subordinated debt and/or sale of equity securities. The Company will also reimburse CSC for its reasonable out-of-pocket expenses associated with the services provided pursuant to the Investment Banking Agreement. As of December 31, 2014 and 2013, the Company accrued $71,504 and $32,424 under the agreement, respectively.



Litigation



The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of December 31, 2014, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company’s business, financial position, results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Taxes [Abstract]
INCOME TAXES	NOTE 14 — INCOME TAXES



	The Company follows Accounting Standards Codification subtopic 740, Income Taxes (“ASC 740”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse.



	The difference between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense is as follows:



		2014				2013
	Income taxes using U.S. federal statutory rate	$	(766,194	)		$	(1,068,708	)
	State income taxes, net of federal benefit		(90,051	)			(108,788	)
	Stock Option Expirations		66,043				78,864
	Net Operating Loss adjustments		(144,824	)			(20,008	)
	Nontaxable Gain on Derivative Instrument		933,477				(9,921	)
	Change in Valuation Allowance		1,549				1,127,875
	Other						686
		$	-			$	—



	At December 31, 2014, the significant components of the deferred tax assets (liabilities) are summarized below:



		2014			2013
	Deferred tax assets:
	Stock Based Compensation	$	4,794,777		$	4,465,854
	Net Operating Losses		36,117,831			35,429,429
	Other		41,469			125,317
	Total deferred tax assets		40,954,077			40,020,600

	Deferred tax liabilities:		-			—
	Total deferred tax liabilities		-			—
	Valuation allowance		40,954,077			40,020,600
	Net deferred tax assets	$			$	—



	As of December 31, 2014 and December 31, 2013, the Company had U.S. federal net operating loss carryforwards of approximately $95.8 million and $94.2 million, respectively, which expire at various dates from 2019 through 2034. These net operating loss carryforwards may be used to offset future taxable income and thereby reduce the Company’s U.S. federal income taxes. Section 382 of the Internal Revenue Code of 1986 (the “Code”) imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership change to use its net operating loss carry forwards to reduce its tax liability. If in the future the Company issues common stock or additional equity instruments convertible in common shares which result in an ownership change exceeding the 50% limitation threshold imposed by section 382 of the Code, the Company’s net operating loss carryforwards may be significantly limited as to the amount of use in a particular years. In addition, all or a portion of the Company’s net operating loss carryforwards may expire unutilized. As of December 31, 2014 and December 31, 2013, the Company had net operating loss carryforwards for state income tax purposes of approximately $95.8 million and $94.2 million, respectively, which expire at various dates from 2019 through 2034.



	The Company has provided a full valuation allowance against its net deferred tax assets, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits of these assets will not be realized.

	The Company complies with the provisions of FASB ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Management has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10.



	The Company is subject to income tax in the U.S., and certain state jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, or any states in connection with income taxes. The Company’s tax years generally remain open to examination for all federal and state tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.



	The Company recognizes interest and penalties related to unrecognized tax benefits, if incurred, as a component of income tax expense.

Fair_Value_Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2014
Fair Value Measurement [Abstract]
FAIR VALUE MEASUREMENT	NOTE 15 — FAIR VALUE MEASUREMENT



	The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:



	Level 1 – Quoted prices in active markets for identical assets or liabilities.



	Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.



	Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.



	All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.



	To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.



	Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.



	The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.



	As of December 31, 2014 or 2013, the Company did not have any items that would be classified as level 1 or 2 disclosures.



	The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in notes 7 and 9. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Notes 8 and 10 are that of volatility and market price of the underlying common stock of the Company.



	As of December 31, 2014 and 2013, the Company did not have any derivative instruments that were designated as hedges.



	The derivative liability as of December 31, 2014, in the amount of $741,271 has a level 3 classification.



	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of December 31, 2014:



			Excess			Warrant				Debt
			Share			Liability				Derivative
			Derivative
	Balance, December 31, 2012		$	390,048			221,179			$	—
	Total (gains) losses
	Initial fair value of debt derivative at note issuance						—				673,219
	Initial fair value of derivative relating to reset warrants			—			—				—
	Mark-to-market at December 31, 2013:			84.906			(74,324	)			(39,761	)
Transfers out of Level 3 upon increase in authorized shares			(474,954	)		—				—
Transfers out of Level 3 upon conversion and settlement of notes										(376,502	)
Balance, December 31, 2013		$	—		$	146,855			$	256,956
Total (gains) losses
Initial fair value of debt derivative at note issuance			—			—				1,443,708
Mark-to-market at December 31, 2014:			—			3,065				(429,018	)
Transfers out of Level 3 upon conversion or payoff of notes payable			—			—				(680,295	)
Balance, December 31, 2014		$	—		$	149,920			$	591,351
Net (Loss) Gain for the period included in earnings relating to the liabilities held at December 31, 2014		$	—		$	(3,065	)		$	429,018



Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. The Company’s stock price increased approximately 5% from December 31, 2013 to December 31, 2014. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments. The simulated fair value of these liabilities is sensitive to changes in the Company’s expected volatility.

Decreases in expected volatility would generally result in a lower fair value measurement. A 10 percent change in pricing inputs and changes in volatilities and correlation factors would result in less than a $129,253 change in our Level 3 fair value.

Subsequent_Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 15 — SUBSEQUENT EVENTS



	Subsequent stock issuances



	In January 2015, the Company issued 4,783,568 shares of its common stock in settlement for services, provided 14,299,567 shares of its common stock in settlement of $49,500 of outstanding convertible notes payable, and $2,981 accrued interest and 2,096,450 shares of its common stock for net proceeds of $16,118 from equity drawdown under the Magna Purchase Agreement.



	In February 2015, the Company sold an aggregate of 1,443,656 shares of its common stock for net proceeds of $16,270. In connection with the stock sale, the Company issued an aggregate of 1,443,656 warrants to purchase the Company’s common stock for five years at $0.01127 per share. In addition, the Company issued 20,219,367 shares of its common stock in settlement of $132,500 of outstanding convertible notes payable and $2,520 accrued interest and 16,556,976 shares of its common stock for net proceeds of $135,645 from equity drawdown under the Magna Purchase Agreement.



	In March 2015, the Company issued 6,185,432 shares of its common stock in settlement of $25,000 of outstanding convertible notes payable and $1,226 accrued interest. In addition, the Company issued 635,357 shares of its common stock as true up shares relating to the February 2015 equity drawdown under the Magna Purchase Agreement.



	Options granted



	On February 2, 2015, the Company granted an aggregate of 7,000,000 options to purchase the Company’s common stock to Board of Directors members at an exercise price of $0.01116 for ten years, vesting immediately.



	Subsequent financing



	On January 7, 2015, the Company entered into a Securities Purchase Agreement with KBM Worldwide, Inc. (“KBM”), for the sale of an 8% convertible note in the principal amount of $38,000 (the “Note”).



	The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on October 9, 2015. The Note is convertible into common stock, at KBM’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.



	On January 28, 2015, the Company entered into a Securities Purchase Agreement with Fourth Man, LLC., for the sale of an 9.5% convertible note in the principal amount of $25,000 (the “Note”).



	The Note bears interest at the rate of 9.5% per annum. All interest and principal must be repaid on January 27, 2016. The Note is convertible into common stock, at Asher’s option, at a 47% discount to the lowest daily closing trading price of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 150%, interest and any other amounts.

	On February 19, 2015, the Company entered into a Securities Purchase Agreement with Vis Vires Group, Inc. (“VIS”), for the sale of an 8% convertible note in the principal amount of $38,000 (the “Note”).



	The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on November 23, 2015. The Note is convertible into common stock, at VIS’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2014
Significant Accounting Policies [Abstract]
Basis and business presentation	Basis and business presentation



	Bioheart, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Our business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. To date, the Company has not generated significant sales revenues to cover costs, incurred expenses, and as a result has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise.
Estimates	Estimates



	The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, revenues and expenses and certain disclosures. The most significant estimates are those used in determination of derivative liabilities and stock compensation. Accordingly, actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition



	The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.



	At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.



	Revenues for test kits and equipment sold are not recorded until test kits are delivered. The Company has revenue sharing arrangements for the sale of goods whereby the Company is the primary obligor, sets pricing with the customers and bears all associated credit risks with the customers. Sales under revenue share arrangements are recorded as gross sales and any portion shared with third parties under such arrangements are classified as selling expense due to the nature of the marketing activities performed by the third party. Revenues from trainings are not recorded until the completion of the training. Any cash received as a deposit for trainings are recorded by the company as a liability.



	Patent treatments and laboratory services revenue are recognized when those services have been completed or satisfied.

	Revenues for bank sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets.


Cash	Cash



	The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.
Accounts Receivable	Accounts Receivable



	Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts



	Any changes to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2014 and 2013, allowance for doubtful accounts was $-0-.
Long-Lived Assets	Long-Lived Assets



	The Company follows FASB ASC 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company determined that there was no impairment on its long-lived assets during 2014 and 2013.
Property and Equipment	Property and Equipment



	Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years.
Income Taxes	Income Taxes



	The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of derivative liability and stock compensation accounting versus tax differences.
Investments	Investments



	The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting.

Comprehensive Income	Comprehensive Income



	The Company does not have any items of comprehensive income in any of the periods presented.

Net loss per Common Share, basic and diluted	Net Loss per Common Share, basic and diluted



	The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options and warrants have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 668,063,786 and 344,241,761 for the years ended December 31, 2014 and 2013, respectively.
Stock based compensation	Stock based compensation



	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of December 31, 2014, there were outstanding stock options to purchase 66,925,209 shares of common stock, 24,814,222 shares of which were vested.
Concentrations of Credit Risk	Concentrations of Credit Risk



	The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.



	As of December 31, 2014, two customers represented 38% and 17%, aggregate of 55% of the Company’s accounts receivable. As of December 31, 2013, three customers represented 36%, 20% and 20%, aggregate of 76%, of the Company’s accounts receivable.



	The Company’s revenues earned from sale of products and services for the year ended December 31, 2014 included 10% of the Company’s total revenues from one customer. For the year ended December 31, 2013, Company’s revenues earned from sale of products and services included 20% of the Company’s total revenues from one customer.
Reliance on Key Personnel and Consultants	Reliance on Key Personnel and Consultants



	The Company has three full-time employees and no part-time employees. The Company is heavily dependent on the continued active participation of its two current executive officers, one employee and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.
Research and Development	Research and Development



	The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $66,420 and $626,983 for the years ended December 31, 2014 and 2013, respectively.
Derivative Instrument Liability	Derivative Instrument Liability



	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2014 and 2013, the Company did not have any derivative instruments that were designated as hedges.



	At December 31, 2014, the Company had outstanding convertible notes that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 10)
Fair Value	Fair Value



	Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.



	The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Reclassification	Reclassification



	Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.
Recent Accounting Pronouncements	Recent Accounting Pronouncements



	In August, 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties About an Entities Ability to Continue as a Going Concern. The standard is intended to define management’s responsibility to decide whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The standard requires management to decide whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The standard provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations in the footnotes. The standard becomes effective in the annual period ending after December 15, 2016, with early application permitted. The adoption of this pronouncement is not expected to have a material impact on the consolidated financial statements. Management’s evaluations regarding the events and conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern have been disclosed in Note 2.



	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	12 Months Ended
Related Party Transactions (Tables)	Dec. 31, 2014
Related Party Transactions [Abstract]
Shedule of notes payable-related party		2014		2013
	Notes payable, Dr Murphy	$	465,240	$	763,626
	Note payable, Dr. Ahn		-		125,000
	Note payable, Mr. Tomas		331,354		518,133
	Note payable, Mr. Tomas		375,000		375,000
	Note payable, Mr. Tomas		500,000		-
	Note payable, Ms. Comella		-		97,718
	Note payable, Ms. Comella		299,465		-
	Total	$	1,971,059	$	1,879,477

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2014
Property and Equipment [Abstract]
Summary of property and equipment

		2014			2013
	Laboratory and medical equipment	$	352,358		$	352,358
	Furniture, fixtures and equipment		125,634			125,634
	Computer equipment		47,647			39,525
	Leasehold improvements		362,046			362,046
			887,685			879,563
	Less accumulated depreciation and amortization		(874,999	)		(870,508	)
		$	12,686		$	9,055

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
Accrued Expenses (Tables)	Dec. 31, 2014
Accrued Expenses [Abstract]
Summary of accrued expenses

		2014		2013
	License and royalty fees	$	—	$	2,122,130
	Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,533,217		1,373,775
	Interest payable on notes payable		685,575		714,180
	Vendor accruals and other		120,836		120,692
	Employee commissions, compensation, etc.		33,987		149,558
		$	2,373,615	$	4,480,335

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
Notes Payable (Tables)	Dec. 31, 2014
Notes Payable [Abstract]
Summary of notes payable



		2014			2013
	Seaside Bank note payable.	$	980,000		$	980,000
	August 2008 Unsecured Promissory Note		—			500,000
	Hunton & Williams notes payable		384,972			384,972
	Asher notes payable		151,000			143,000
	Daniel James Management note payable		75,000			—
	Fourth Man, LLC note payable		75,000			35,000
	Magna Group		205,000			—
	Total notes payable		1,870,972			2,042,972
	Less unamortized debt discount		(339,160	)		(112,131	)
	Total notes payable net of unamortized debt discount	$	1,531,812		$	1,930,841

Stock_Options_and_Warrants_Tab

Stock Options and Warrants (Tables)	12 Months Ended
Stock Options and Warrants (Tables)	Dec. 31, 2014
Stock Options and Warrants [Abstract]
Summary of options and activity

		Shares			Weighted-		Weighted-
					Average		Average
					Exercise Price		Remaining
							Contractual
							Term (in years)

	Options outstanding at January 1, 2013		7,853,376		$	0.67	8.2
	Granted		17,400,000		$	0.016	9.9
	Exercised		—		$
	Forfeited/Expired		(1,340,433	)	$	1.08
	Options outstanding at December 31, 2013		23,912,943		$	0.15	9
	Granted		43,148,487		$	0.023	10
	Exercised		—
	Forfeited/Expired		(136,221	)	$	5.2
	Options outstanding at December 31, 2014		66,925,209		$	0.056	8.9
	Options exercisable at December 31, 2014		24,814,222		$	0.12	8.7
	Available for grant at December 31, 2014		96,500,000


Summary of options outstanding and exercisable for stock-based payment awards		Options Outstanding					Options Exercisable
		Shares		Weighted-	Weighted-		Shares		Weighted-
				Average	Average				Average
				Remaining	Exercise				Exercise
				Contractual	Price				Price
				Term

	$0.00 – $0.70	66,438,487		9	$	0.03	24,327,500		$	0.03
	$0.71 – $1.28	149,930		3.8	$	0.81	149,930		$	0.81
	$5.25 – $5.67	312,080		1.6	$	5.53	312,080		$	5.53
	$7.69	24,712		1.6	$	7.69	24,712		$	7.69
		66,925,209		8.9	$	0.056	24,814,222		$	0.12


Summary of warrants and activity		Shares			Weighted-			Weighted-
					Average			Average
					Exercise			Remaining
					Price			Contractual
								Term (in years)

	Outstanding at January 1, 2013		74,073,322		$	0.37			4.5
	Issued		50,350,536		$	0.16			9.2
	Exercised		—		$	0
	Forfeited		(6,345,002	)	$	0.38
	Outstanding at December 31, 2013		118,078,856		$	0.22			6.3
	Issued		57,582,469		$	0.02			8.2
	Exercised		(11,918,181	)	$	0.01
	Expired		(13,178,145	)	$	0.08
	Outstanding at December 31, 2014		150,564,999		$	0.17			6.6
	Exercisable at December 31, 2014		131,822,688		$	0.1			6.7


Summary of warrants outstanding and exercisable

		Warrants Outstanding									Warrants Exercisable
			Shares			Weighted-			Weighted-			Shares		Weighted-
						Average			Average					Average
						Remaining			Exercise					Exercise
						Contractual			Price					Price
						Term

	$0.01 – $0.50		144,315,866			6.7		$	0.02			127,118,005	$	0.02
	$0.52 – $0.68		2,699,675			4.3		$	0.58			2,699,675	$	0.58
	$0.70 – $1.62		848,176			5		$	0.71			848,176	$	0.71
	$5.67 – $7.69		2,701,282			7.9		$	7.55			1,156,832	$	7.35
			150,564,999			6.6		$	0.17			131,822,688	$	0.1

Commiments_and_Contingencies_T

Commiments and Contingencies (Tables)	12 Months Ended
Commiments and Contingencies (Tables)	Dec. 31, 2014
Commitments and Contingencies [Abstract]
Schedule of future minimum lease obligations under non cancelable operating lease agreements

	Year ending December 31,
	2015	$	86,382
	2016		43,830
	Total	$	130,212

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Taxes [Abstract]
Schedule of difference between income tax expenses

		2014				2013
	Income taxes using U.S. federal statutory rate	$	(766,194	)		$	(1,068,708	)
	State income taxes, net of federal benefit		(90,051	)			(108,788	)
	Stock Option Expirations		66,043				78,864
	Net Operating Loss adjustments		(144,824	)			(20,008	)
	Nontaxable Gain on Derivative Instrument		933,477				(9,921	)
	Change in Valuation Allowance		1,549				1,127,875
	Other						686
		$	-			$	—


Components of the deferred tax assets (liabilities)

		2014			2013
	Deferred tax assets:
	Stock Based Compensation	$	4,794,777		$	4,465,854
	Net Operating Losses		36,117,831			35,429,429
	Other		41,469			125,317
	Total deferred tax assets		40,954,077			40,020,600

	Deferred tax liabilities:		-			—
	Total deferred tax liabilities		-			—
	Valuation allowance		40,954,077			40,020,600
	Net deferred tax assets	$			$	—

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	12 Months Ended
Fair Value Measurement (Tables)	Dec. 31, 2014
Fair Value Measurement [Abstract]
Summary of changes in fair value of the Company's Level 3 financial liabilities

		Excess			Warrant			Debt
		Share			Liability			Derivative
		Derivative
	Balance, December 31, 2012	$	390,048			221,179		$	—
	Total (gains) losses
	Initial fair value of debt derivative at note issuance					—			673,219
	Initial fair value of derivative relating to reset warrants		—			—			—
	Mark-to-market at December 31, 2013:		84.906			(74,324	)		(39,761	)
	Transfers out of Level 3 upon increase in authorized shares		(474,954	)		—			—
	Transfers out of Level 3 upon conversion and settlement of notes								(376,502	)
	Balance, December 31, 2013	$	—		$	146,855		$	256,956
	Total (gains) losses
	Initial fair value of debt derivative at note issuance		—			—			1,443,708
	Mark-to-market at December 31, 2014:		—			3,065			(429,018	)
	Transfers out of Level 3 upon conversion or payoff of notes payable		—			—			(680,295	)
	Balance, December 31, 2014	$	—		$	149,920		$	591,351
	Net (Loss) Gain for the period included in earnings relating to the liabilities held at December 31, 2014	$	—		$	(3,065	)	$	429,018

Significant_Accounting_Policie2

Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	Employees	Dec. 31, 2013	Dec. 31, 2012
Significant Accounting Policies (Textual)
Number of fully diluted shares outstanding	668,063,786	344,241,761
Number of full time employees	3
Number of part time employees
Research and development expense	$66,420	$626,983
Allowance for doubtful accounts	$0	$0
Percentage of ownership in new entity	33.00%
Minimum [Member]
Significant Accounting Policies (Textual)
Property and equipment, estimated useful lives	3 years
Maximum [Member]
Significant Accounting Policies (Textual)
Property and equipment, estimated useful lives	15 years
Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)
Concentration Risk, Percentage		20.00%
Revenues earned from sale of products and services percentage	10.00%
Number of customers accounted for revenue	1
Employee Stock Option [Member]
Significant Accounting Policies (Textual)
Option outstanding to purchase common stock	66,925,209	23,912,943	7,853,376
Options vested	24,814,222
Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)
Concentration Risk, Percentage	55.00%	76.00%
Number of customer accounted for accounts receivable	2	3
Accounts Receivable [Member] \| Customer One [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)
Concentration Risk, Percentage	38.00%	36.00%
Accounts Receivable [Member] \| Customer Two [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)
Concentration Risk, Percentage	17.00%	20.00%
Accounts Receivable [Member] \| Customer Three [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies (Textual)
Concentration Risk, Percentage		20.00%

Going_Concern_Matters_Details

Going Concern Matters (Details) (USD $)	12 Months Ended
Going Concern Matters (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Going Concern Matters (Textual)
Net losses	($2,253,511)	($3,143,259)
Net cash used in operating activities	($1,108,647)	($1,913,326)

Investments_Details

Investments (Details) (USD $)	12 Months Ended
Investments (Details) (USD $)	Dec. 31, 2014
Investments Textual [Abstract]
Ownership percentage	33.00%
Cash and expenses paid	$49,714
Other income/expense	-9,117
Carrying value of the investment	40,597
U.S. Stem Cell Clinic, LLC [Member]
Investments Textual [Abstract]
Ownership percentage	33.00%
Cash and expenses paid	49,714
Percentage of loss incurred	33.00%
Other income/expense	9,117
Carrying value of the investment	$40,597

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Summary of property and equipment
Laboratory and medical equipment	$352,358	$352,358
Furniture, fixtures and equipment	125,634	125,634
Computer equipment	47,647	39,525
Leasehold improvements	362,046	362,046
Property and equipment, Gross	887,685	879,563
Less accumulated depreciation and amortization	-874,999	-870,508
Property and equipment, net	$12,686	$9,055

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Summary of accrued expenses
License and royalty fees		$2,122,130
Amounts payable to the Guarantors of the Company's loan agreement with Bank of America and Seaside Bank, including fees and interest	1,533,217	1,373,775
Interest payable on notes payable	685,575	714,180
Vendor accruals and other	120,836	120,692
Employee commissions, compensation, etc.	33,987	149,558
Accrued expenses, Total	$2,373,615	$4,480,335

Accrued_Expenses_Details_Textu

Accrued Expenses (Details Textual) (USD $)	0 Months Ended	12 Months Ended		1 Months Ended
Accrued Expenses (Details Textual) (USD $)	Oct. 03, 2014	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2013
Accrued Expenses Textual [Abstract]
Shares issued in conversion of debt		48,584,542	57,967,906
Settlement of debt related to accrual interest		$2,122,130
Net gain in settlement of debt		120,656
Accrued interest	12,705	12,635	598,125
Gain (loss) on settlement of note payable			1,078,625
Common Stock [Member]
Accrued Expenses Textual [Abstract]
Amount of debt exchanged for shares			$500,000
Shares issued in conversion of debt			1,000,000	1,995,614
Common market price			$0.02
Number of debt holder			1

Standby_Equity_Distribution_Ag1

Standby Equity Distribution Agreement (Details) (USD $)	0 Months Ended	12 Months Ended
Standby Equity Distribution Agreement (Details) (USD $)	Nov. 02, 2011	Dec. 31, 2014	Dec. 31, 2013
Standby Equity Distribution Agreement (Textual)
Funds contributed by Greystone	$1,000,000
Period for which funding is provided	24 months
Transaction description of agreement with affiliates		For each share of the Company common stock purchased under the Agreement, Greystone will pay eighty percent (80%) of the average of the lowest daily volume weighted average price for five consecutive trading days immediately preceding Advance Notice (the "Valuation Period") commencing the date an Advance Notice (the "Advance Notice") is delivered to Greystone in a manner provided by the Agreement.
Aggregate common stock share issued			31,052,141
Amount draw down on the equity line due to issuance of common stock			$346,914
Description of purchase price adjustment under equity line		The parties to the Equity Line agreed that the Purchase Price be adjusted to seventy-five percent (75%) of the lowest daily volume weighted average price of the Common Stock as quoted by Bloomberg, LP, during the five (5) consecutive Trading Days (as such term is defined in the Equity Line) immediately subsequent to the date of the relevant Advance Notice.

Stock_Purchase_Agreement_Detai

Stock Purchase Agreement (Details) (USD $)	1 Months Ended
Stock Purchase Agreement (Details) (USD $)	Oct. 23, 2014	Dec. 31, 2014	Dec. 31, 2013
Stock Purchase Agreement (Textual)
Common stock value		$581,433	$379,788
Common stock, par value		$0.00	$0.00
Common Stock Purchase Agreement [Member]
Stock Purchase Agreement (Textual)
Common stock value	$3,000,000
Common stock, par value	$0.00
Agreement term	24 months
Purchase price	$0.00
Purchase price description	The "Initial Purchase Price" is defined as a price equal to 93% of the lowest of (i) the arithmetic average of the three lowest daily volume weighted average prices for the Company's common stock (the "VWAP") during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date, (ii) the arithmetic average of the three lowest closing sale prices for the Company's common stock during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date and (iii) the closing sale price for the Company's common stock on the trading day immediately preceding the applicable Draw Down Exercise Date.
Common stock issued as commitment shares in connection with equity purchase agreement, Shares	12,000,000

Notes_Payable_Details

Notes Payable (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Oct. 25, 2010
Summary of notes payable
Total notes payable	$1,870,972	$2,042,972
Less unamortized debt discount	-339,160	-112,131
Total notes payable net of unamortized debt discount	1,531,812	1,930,841
Seaside Bank note payable [Member]
Summary of notes payable
Total notes payable	980,000	980,000	980,000
August 2008 Unsecured Promissory Note [Member]
Summary of notes payable
Total notes payable
Hunton & Williams notes payable [Member]
Summary of notes payable
Total notes payable	384,972	384,972
Asher notes payable [Member]
Summary of notes payable
Total notes payable	151,000	143,000
Daniel James management note payable [Member]
Summary of notes payable
Total notes payable	75,000
Fourth Man, LLC note payable [Member]
Summary of notes payable
Total notes payable	$75,000	$35,000

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)	0 Months Ended	12 Months Ended		1 Months Ended	0 Months Ended		1 Months Ended		0 Months Ended
Notes Payable (Details Textual) (USD $)	Oct. 03, 2014	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Oct. 25, 2010	Jun. 16, 2014	Apr. 30, 2009	Aug. 20, 2008	Oct. 11, 2013	Oct. 02, 2015	Jul. 08, 2015	Oct. 06, 2014	Jul. 01, 2014	Aug. 01, 2013
Notes Payable (Textual)
Notes payable		$1,870,972	$2,042,972
Effective interest rate										9.50%	8.00%	8.00%	5.00%	5.00%
Accrued interest	12,705	12,635	598,125
Gain (loss) on settlement of note payable			1,078,625
Outstanding principal amount of debt												38,000
Amortization of debt discount		546,970	368,682
Shares issued in conversion of debt		48,584,542	57,967,906
Outstanding principal amount		62,500
Proceeds from notes payable		740,500	415,500
Magna [Member]
Notes Payable (Textual)
Effective interest rate		12.00%
Debt instrument, Maturity date		7-Aug-15
Fair value of embedded derivatives		1,443,708	387,983
Interest expense		675,708	-97,483
Dividend yield		0.00%	0.00%
Notes payable, Principle value		307,500
Amortization costs and discounts operations as interest expense		575,629	368,682
Outstanding principal amount		40,000
Original interest discount		102,500
Original interest discount in percentage		33.33%
Amount reduced in note payable		102,500
Fixed conversion price		$0.01
Note conversion, description		This conversion price represents a discount of approximately 45% from the lowest trading price the Company common stock during the five trading days prior to October 7, 2014, the date the Company issued the Convertible Note to Magna.
Remaining principle balance of notes payable		205,000
Proceeds from notes payable		768,000	-290,500
Magna [Member] \| Maximum [Member]
Notes Payable (Textual)
Expected volatility		171.91%	164.29%
Risk free rate		0.25%	0.17%
Expected Term		1 year	9 months 7 days
Estimated fair value of the Company's common stock		$0.05	$0.04
Magna [Member] \| Minimum [Member]
Notes Payable (Textual)
Expected volatility		146.33%	154.80%
Risk free rate		0.10%	0.07%
Expected Term		9 months 4 days	6 months
Estimated fair value of the Company's common stock		$0.01	$0.01
Common stock [Member]
Notes Payable (Textual)
Common stock issued in connection with issuance of convertible debt, Shares			2,500,000
Amount of debt exchanged for shares			500,000
Shares issued in conversion of debt			1,000,000	1,995,614
Fixed conversion price			$0.02
Seaside Bank note payable [Member]
Notes Payable (Textual)
Notes payable		980,000	980,000		980,000
Effective interest rate					4.25%
Debt instrument, Maturity date					23-Dec-15
August 2008 Unsecured Promissory Note [Member]
Notes Payable (Textual)
Notes payable
Borrowings from third party								1,000,000
Effective interest rate								13.50%
Debt instrument, Maturity date								31-May-10
Gross proceeds from private placement								19,000,000
Occurrence period of repayment of loan								Within 12 months
Warrant issued to purchase common stock							451,053
Warrant exercise price							$0.53
Fair value of warrant issued							195,694
Accrued interest						81,568
Gain (loss) on settlement of note payable						255,890
Notes payable, Principle value						500,000
Shares issued in conversion of debt			1,000,000			14,539,191
Hunton & Williams notes payable [Member]
Notes Payable (Textual)
Notes payable		384,972	384,972
Number of outstanding notes payable		2	2
Hunton & Williams notes payable [Member] \| Note payable one [Member]
Notes Payable (Textual)
Effective interest rate		8.00%	8.00%
Outstanding notes payable		61,150	61,150
Hunton & Williams notes payable [Member] \| Note payable two [Member]
Notes Payable (Textual)
Effective interest rate		8.00%	8.00%
Outstanding notes payable		323,822	323,822
Asher notes payable [Member]
Notes Payable (Textual)
Notes payable		151,000	143,000
Effective interest rate		8.00%	8.00%
Debt instrument, Maturity date		12-Aug-15	7-Aug-14
Description of note payable		The Notes are convertible into common stock, at Asher's option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.	The Notes are convertible into common stock, at Asher's option, at a 42% to 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.
Fair value of embedded derivatives		566,294	335,089
Recorded fair value of derivatives and faire value of each subsequent reporting date		149,770
Amortization of debt discount		248,153	255,500
Interest expense			79,589
Dividend yield			0.00%
Notes payable, Principle value		334,000	255,500
Amortization of financing costs and discounts		92,794	162,706
Notes payable remaining principle balance		0
Asher notes payable [Member] \| Maximum [Member]
Notes Payable (Textual)
Percentage of discount to the lowest closing price prior to conversion			45.00%
Expected volatility			164.29%
Risk free rate			0.17%
Expected Term			9 months 7 days
Estimated fair value of the Company's common stock			$0.04
Asher notes payable [Member] \| Minimum [Member]
Notes Payable (Textual)
Percentage of discount to the lowest closing price prior to conversion			42.00%
Expected volatility			154.80%
Risk free rate			0.09%
Expected Term			8 months 1 day
Estimated fair value of the Company's common stock			$0.01
Daniel Notes [Member]
Notes Payable (Textual)
Effective interest rate		8.00%
Debt instrument, Maturity date		30-Nov-15
Increase in sale percentage		9.50%
Description of note payable		The Daniel Notes are convertible into common stock, at holder's option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.
Fair value of embedded derivatives		236,211
Recorded fair value of derivatives and faire value of each subsequent reporting date		95,866
Amortization of debt discount		76,758
Notes payable, Principle value		135,000
Notes payable remaining principle balance		75,000
Fourth Man, LLC note payable [Member]
Notes Payable (Textual)
Notes payable		75,000	35,000
Effective interest rate		8.00%							8.00%
Debt instrument, Maturity date		28-Aug-15							10-Apr-14
Increase in sale percentage		9.50%
Description of note payable		The Notes are convertible into common stock, at Fourth Man's option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.							The Note is convertible into common stock, at Fourth Man's option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.
Fair value of embedded derivatives		168,501							52,894
Recorded fair value of derivatives and faire value of each subsequent reporting date		93,505
Amortization of debt discount		50,549							35,000
Interest expense									17,894
Dividend yield									0.00%
Expected volatility									164.29%
Risk free rate									0.07%
Expected Term									6 months
Estimated fair value of the Company's common stock									$0.01
Notes payable, Principle value		100,000							35,000
Amortization of financing costs and discounts		19,337	15,663
Notes payable remaining principle balance		75,000
Fourth Man, LLC note payable [Member] \| Maximum [Member]
Notes Payable (Textual)
Effective interest rate		9.50%
Fourth Man, LLC note payable [Member] \| Minimum [Member]
Notes Payable (Textual)
Effective interest rate		8.00%
Asher Daniel ad Fourth man notes payable [Member]
Notes Payable (Textual)
Fair value of embedded derivatives		1,443,708
Amortization of debt discount		-675,708
Dividend yield		0.00%
Amortization of financing costs and discounts		575,629	368,629
Asher Daniel ad Fourth man notes payable [Member] \| Maximum [Member]
Notes Payable (Textual)
Expected volatility		171.91%
Risk free rate		0.25%
Expected Term		1 year
Estimated fair value of the Company's common stock		$0.05
Asher Daniel ad Fourth man notes payable [Member] \| Minimum [Member]
Notes Payable (Textual)
Expected volatility		146.33%
Risk free rate		0.10%
Expected Term		9 months 4 days
Estimated fair value of the Company's common stock		$0.01
Derivative Financial Instruments [Member] \| Magna [Member]
Notes Payable (Textual)
Fair value of embedded derivatives		472,702
Fair value of derivatives		252,211
Amortization costs and discounts operations as interest expense		57,319
Fair value of derivative liability		$128,624

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Notes payable	$1,971,059	$1,879,477
Dr Murphy [Member]
Related Party Transaction [Line Items]
Notes payable	465,240	763,626
Dr Ahn [Member]
Related Party Transaction [Line Items]
Notes payable		125,000
Mr. Tomas [Member]
Related Party Transaction [Line Items]
Notes payable	331,354	518,133
Mr. Tomas [Member]
Related Party Transaction [Line Items]
Notes payable	375,000	375,000
Mr. Tomas [Member]
Related Party Transaction [Line Items]
Notes payable	500,000
Ms. Comella [Member]
Related Party Transaction [Line Items]
Notes payable		97,718
Ms. Comella [Member]
Related Party Transaction [Line Items]
Notes payable	$299,465

Related_Party_Transaction_Deta

Related Party Transaction (Details Textual) (USD $)	0 Months Ended	12 Months Ended		1 Months Ended	0 Months Ended			1 Months Ended	12 Months Ended	1 Months Ended	0 Months Ended			1 Months Ended
Related Party Transaction (Details Textual) (USD $)	Oct. 03, 2014	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 24, 2013	Oct. 01, 2012	Sep. 21, 2012	Feb. 28, 2013	Dec. 31, 2012	Mar. 30, 2012	Jul. 01, 2014	Jul. 05, 2014	Oct. 09, 2012	Jun. 20, 2014	Oct. 02, 2015	Jul. 08, 2015	Oct. 06, 2014	Aug. 01, 2013	Feb. 29, 2012	Nov. 30, 2012	Jun. 04, 2011	Aug. 01, 2014
Related Party Transactions (Textual)
Advances, related party		$148,759	$416,198															$22,750
Outstanding principal amount of debt																	38,000
Subordinated debt, related party		1,500,000	1,500,000
Effective interest rate											5.00%				9.50%	8.00%	8.00%	5.00%
Common stock issued as payment,shares				8,771,929
Advances of cash				100,000
Common stock issued in settlement of related party notes payable			537,750
Aggregate issue of shares		10,232,286
Settlement of related party advances		298,759
Common stock issued in lieu of payment	514,886	274,681
Debt Instrument, Increase, Accrued Interest	12,705	12,635	598,125
Shares issued in conversion of debt		48,584,542	57,967,906
Common stock [Member]
Related Party Transactions (Textual)
Common stock issued in settlement of related party notes payable			44,890
Amount issued in conversion of debt			500,000
Shares issued in conversion of debt			1,000,000	1,995,614
Preferred stock [Member]
Related Party Transactions (Textual)
Common stock issued in settlement of related party notes payable
Accrued Liabilities [Member]
Related Party Transactions (Textual)
Amount issued in conversion of debt					85,447
Shares issued in conversion of debt					3,915,662
Northstar Biotechnology Group, LLC Promissory Note [Member]
Related Party Transactions (Textual)
Outstanding principal amount of debt		362,000	362,000																544,267
Common stock purchase warrants issued							5,000,000
Series A convertible preferred stock issued in exchange for payments		20,000,000	5,000,000			5,000,000			5,000,000
Common stock issued in exchange for payments			10,000,000			10,000,000
Value of debt outstanding			210,000			210,000
Percentage of revenues to be received as royalty						8.00%
Effective interest rate						12.85%		7.00%
Convertible preferred stock issued for penalty settlement			15,000,000
Fair value for Preferred Stock			274,050
Common Stock, Voting Rights									25 votes
Preferred Stock, Voting Rights									20 votes.
Promissory Note [Member]
Related Party Transactions (Textual)
Repayment terms										The first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012.
Officer and Employee [Member]
Related Party Transactions (Textual)
Debt instrument, Maturity date											1-Jan-15
Dr Murphy [Member]
Related Party Transactions (Textual)
Advances, related party														2,000
Outstanding principal amount of debt		465,240	763,626
Effective interest rate																		5.00%
Outstanding balance of subordinated notes																				100,000	140,000
Debt instrument, Maturity date												1-Jun-15	9-Oct-13
Common stock issued in settlement of related party notes payable														298,386
Dr Ahn [Member]
Related Party Transactions (Textual)
Outstanding principal amount of debt			125,000
Percentage of revenues to be received as royalty			8.00%
Common stock issued in settlement of related party notes payable,Shares		4,045,796
Common stock issued in settlement of related party notes payable		125,000
Accured interest		36,832
Outstanding promissory notes			0
Mr. Tomas [Member]
Related Party Transactions (Textual)
Outstanding principal amount of debt		331,354									375,000,000											375,000
Effective interest rate											5.00%
Face value of note											500,000							375,000
Outstanding promissory notes		375,000
Ms. Comella [Member]
Related Party Transactions (Textual)
Outstanding principal amount of debt		299,465																0
Fair value for Preferred Stock		97,718	27,282															125,000
Effective interest rate											5.00%							5.00%
Face value of note											300,000
Outstanding promissory notes											535

Derivative_Liabilities_Details

Derivative Liabilities (Details) (USD $)	0 Months Ended	12 Months Ended	0 Months Ended	12 Months Ended
Derivative Liabilities (Details) (USD $)	Feb. 04, 2013	Dec. 31, 2013	Oct. 01, 2012	Dec. 31, 2014
Excessive Committed Shares [Member]
Derivative Liabilities (Textual)
Increase in common stock, shares, authorized	970,000,000
Fair value of derivative liability	$474,954
Dividend yield	0.00%
Expected volatility	156.52%
Risk free rate	0.38%
Expected Term	3 years 6 months
Loss on change in derivatives		84,907
Reset Warrants [Member]
Derivative Liabilities (Textual)
Fair value of derivative liability				149,920
Dividend yield				0.00%
Expected volatility				146.33%
Risk free rate				1.97%
Expected Term				7 years 9 months
Loss on change in derivatives				3,064
Common stock purchase warrants issued			15,000,000
Exercise price of warrant			$0.01
Warrants exercisable period			10 years
Convertible Notes Payable [Member]
Derivative Liabilities (Textual)
Fair value of embedded derivatives				591,351
Dividend yield				0.00%
Expected volatility				146.33%
Loss on change in derivatives				$429,018
Fair value of common stock				$0.01
Convertible Notes Payable [Member] \| Minimum [Member]
Derivative Liabilities (Textual)
Risk free rate				0.04%
Expected Term				2 months 27 days
Convertible Notes Payable [Member] \| Maximum [Member]
Derivative Liabilities (Textual)
Risk free rate				0.25%
Expected Term				11 months 1 day

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	12 Months Ended			1 Months Ended	0 Months Ended
Stockholders' Equity (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2013	Aug. 17, 2012
Stockholders' Equity (Textual)
Preferred stock, shares issued	20,000,000	20,000,000
Preferred stock, par value	$0.00	$0.00
Preferred Stock, Shares Authorized	20,000,000	20,000,000
Common stock, par value	$0.00	$0.00
Common Stock, Shares Authorized	2,000,000,000	950,000,000
Issuance of common stock	$479,625	$865,000
Issuance of common stock, Shares	42,066,606
Shares issued in conversion of debt	48,584,542	57,967,906
Gain/ loss on settlement of debt	120,656
Common stock issued upon conversion of notes payable	2,057,280
Common stock issued upon conversion of notes payable and accured interest, Share	83,236,247	2,500,000
Gain in settlement of debt	255,890
Common stock issued for services	183,991	85,151
Common stock issued under standby equity distribution agreement		31,052,141
Common stock issued for settlement of related party notes payable and advances		34,890,348
Common stock issued upon settlement of interest and penalty in connection with convertible debt		9,408,718
Northstar Biotechnology Group, LLC Promissory Note [Member]
Stockholders' Equity (Textual)
Preferred Stock, Voting Rights			20 votes.
Accounts Payable and Accrued Liabilities [Member]
Stockholders' Equity (Textual)
Shares issued in conversion of debt	48,584,542	5,656,340
Amount of debt exchanged for shares		82,339
Gain/ loss on settlement of debt	57,025	74,877
Common Stock [Member]
Stockholders' Equity (Textual)
Issuance of common stock		50,029
Issuance of common stock, Shares		50,029,227
Shares issued in conversion of debt		1,000,000		1,995,614
Amount of debt exchanged for shares		500,000
Common stock issued for services	$3,840	$6,220
Common stock issued for services, Shares	3,839,832	6,220,263
Common stock issued upon exercise of warrants, Shares	11,918,181
Common stock issued as commitment shares in connection with equity purchase agreement, Shares	12,000,000
Series A Convertible Preferred Stock [Member]
Stockholders' Equity (Textual)
Preferred stock designated as Series A Convertible Preferred Stock					5,000,000
Preferred stock shares increased					20,000,000
Preferred stock, shares issued		20,000,000
Series A Convertible Preferred Stock [Member] \| Northstar Biotechnology Group, LLC Promissory Note [Member]
Stockholders' Equity (Textual)
Preferred Stock, Voting Rights					Voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders.

Stock_Options_and_Warrants_Det

Stock Options and Warrants (Details) (Stock Options [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Options [Member]
Summary of options and activity
Options outstanding, Beginning Balance	23,912,943	7,853,376
Granted, shares	43,148,487	17,400,000
Exercised, Shares
Forfeited/Expired, Shares	-136,221	-1,340,433
Options outstanding, Ending Balance	66,925,209	23,912,943	7,853,376
Options Exercisable, Shares	24,814,222
Available for grant, Shares	96,500,000
Options outstanding, Weighted - Average Exercise Price, Beginning Balance	$0.15	$0.67
Granted, Weighted - Average Exercise Price	$0.02	$0.02
Forfeited/Expired, Weighted - Average Exercise Price	$5.20	$1.08
Options outstanding, Weighted - Average Exercise Price, Balance	$0.06	$0.15	$0.67
Options exercisable, Weighted - Average Exercise Price	$0.12
Options Exercised, Weighted - Average Remaining Contractual Term	10 years	9 years 10 months 24 days
Options outstanding, Weighted - Average Remaining Contractual Term (in years)	8 years 10 months 24 days	9 years	8 years 2 months 12 days
Options exercisable, Weighted - Average Remaining Contractual Term (in years)	8 years 8 months 12 days

Stock_Options_and_Warrants_Det1

Stock Options and Warrants (Details 1) (Stock Options [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Options outstanding and exercisable for stock-based payment awards
Options Outstanding, Shares	66,925,209
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 10 months 24 days
Options Outstanding, Weighted- Average Exercise Price	$0.06
Options Exercisable, Shares	24,814,222
Options Exercisable, Weighted-Average Exercise Price	$0.12
$0.00 - $0.70 [Member]
Options outstanding and exercisable for stock-based payment awards
Range of Exercise Prices, Minimum	$0
Range of Exercise Prices, Maximum	$0.70
Options Outstanding, Shares	66,438,487
Options Outstanding, Weighted-Average Remaining Contractual Term	9 years
Options Outstanding, Weighted- Average Exercise Price	$0.03
Options Exercisable, Shares	24,327,500
Options Exercisable, Weighted-Average Exercise Price	$0.03
$0.71 - $1.28 [Member]
Options outstanding and exercisable for stock-based payment awards
Range of Exercise Prices, Minimum	$0.71
Range of Exercise Prices, Maximum	$1.28
Options Outstanding, Shares	149,930
Options Outstanding, Weighted-Average Remaining Contractual Term	3 years 9 months 18 days
Options Outstanding, Weighted- Average Exercise Price	$0.81
Options Exercisable, Shares	149,930
Options Exercisable, Weighted-Average Exercise Price	$0.81
$5.25 - $5.67 [Member]
Options outstanding and exercisable for stock-based payment awards
Range of Exercise Prices, Minimum	$5.25
Range of Exercise Prices, Maximum	$5.67
Options Outstanding, Shares	312,080
Options Outstanding, Weighted-Average Remaining Contractual Term	1 year 7 months 6 days
Options Outstanding, Weighted- Average Exercise Price	$5.53
Options Exercisable, Shares	312,080
Options Exercisable, Weighted-Average Exercise Price	$5.55
$7.69 [Member]
Options outstanding and exercisable for stock-based payment awards
Range of Exercise Prices	$7.69
Options Outstanding, Shares	24,712
Options Outstanding, Weighted-Average Remaining Contractual Term	1 year 7 months 6 days
Options Outstanding, Weighted- Average Exercise Price	$7.69
Options Exercisable, Shares	24,712
Options Exercisable, Weighted-Average Exercise Price	$7.69

Stock_Options_and_Warrants_Det2

Stock Options and Warrants (Details 2) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Summary of warrants and activity
Options outstanding, Beginning Balance	118,078,856	74,073,322
Options outstanding, Weighted - Average Exercise Price, Beginning Balance	$0.22	$0.37
Warrants outstanding, Weighted - Average Remaining Contractual Term (in years)	6 years 3 months 18 days	4 years 6 months
Shares, issued	57,582,469	50,350,536
Warrants, Weighted-Average Exercise Price	$0.02	$0.16
Warrants, Weighted Average Remaining Contractual Term (in years)	8 years 2 months 12 days	9 years 2 months 12 days
Exercised, Shares	-11,918,181
Exercised, Weighted - Average Exercise Price	$0.01	$0
Forfeited/Expired, Shares	-13,178,145	-6,345,002
Forfeited/Expired, Weighted - Average Exercise Price	$0.08	$0.38
Options outstanding, Ending Balance	150,564,999	118,078,856
Options outstanding, Weighted - Average Exercise Price, Balance	$0.17	$0.22
Options outstanding, Weighted - Average Remaining Contractual Term	6 years 8 months 12 days	6 years 3 months 18 days
Options Exercisable, Shares	131,822,688
Options exercisable, Weighted - Average Exercise Price	$0.10
Warrants exercisable, Weighted - Average Remaining Contractual Term (in years)	6 years 7 months 6 days

Stock_Options_and_Warrants_Det3

Stock Options and Warrants (Details 3) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Warrants outstanding and exercisable
Warrants Outstanding, Shares	150,564,999
Warrants Outstanding, Weighted-Average Remaining Contractual Term	6 years 7 months 6 days
Warrants Outstanding, Weighted- Average Exercise Price	$0.17
Warrants Exercisable, Shares	131,822,688
Warrants Exercisable, Weighted-Average Exercise Price	$0.10
0.01 - $0.50 [Member]
Warrants outstanding and exercisable
Range of Exercise Prices, Minimum	$0.01
Range of Exercise Prices, Maximum	$0.50
Warrants Outstanding, Shares	144,315,866
Warrants Outstanding, Weighted-Average Remaining Contractual Term	6 years 8 months 12 days
Warrants Outstanding, Weighted- Average Exercise Price	$0.02
Warrants Exercisable, Shares	127,118,005
Warrants Exercisable, Weighted-Average Exercise Price	$0.02
0.52 - $0.68 [Member]
Warrants outstanding and exercisable
Range of Exercise Prices, Minimum	$0.52
Range of Exercise Prices, Maximum	$0.68
Warrants Outstanding, Shares	2,699,675
Warrants Outstanding, Weighted-Average Remaining Contractual Term	4 years 3 months 18 days
Warrants Outstanding, Weighted- Average Exercise Price	$0.58
Warrants Exercisable, Shares	2,699,675
Warrants Exercisable, Weighted-Average Exercise Price	$0.58
0.70 - $1.62 [Member]
Warrants outstanding and exercisable
Range of Exercise Prices, Minimum	$0.70
Range of Exercise Prices, Maximum	$1.62
Warrants Outstanding, Shares	848,176
Warrants Outstanding, Weighted-Average Remaining Contractual Term	5 years
Warrants Outstanding, Weighted- Average Exercise Price	$0.71
Warrants Exercisable, Shares	848,176
Warrants Exercisable, Weighted-Average Exercise Price	$0.71
5.67 - $7.69 [Member]
Warrants outstanding and exercisable
Range of Exercise Prices, Minimum	$5.67
Range of Exercise Prices, Maximum	$7.69
Warrants Outstanding, Shares	2,701,282
Warrants Outstanding, Weighted-Average Remaining Contractual Term	7 years 10 months 24 days
Warrants Outstanding, Weighted- Average Exercise Price	$7.55
Warrants Exercisable, Shares	1,156,832
Warrants Exercisable, Weighted-Average Exercise Price	$7.35

Stock_Options_and_Warrants_Det4

Stock Options and Warrants (Details Textual) (USD $)	12 Months Ended		0 Months Ended					1 Months Ended	0 Months Ended
Stock Options and Warrants (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Feb. 24, 2014	Nov. 03, 2014	12-May-14	Sep. 01, 2013	Aug. 05, 2013	Aug. 31, 2014	Aug. 01, 2013
Stock Options and Warrants (Textual)
Interest expense	$1,639,571	$1,437,883
Fair value of the option vested	537,606	125,515
Officer [Member]
Stock Options and Warrants (Textual)
Options to purchase the Company's common stock			15,000,000
Exercise price			$0.02
Stock option vesting right percentage			25.00%
Stock option exercisable period			10 years
Fair value of the option vested			282,597
Dividend yield			0.00%
Volatility			163.63%
Risk free rate			2.75%
Officer One [Member]
Stock Options and Warrants (Textual)
Options to purchase the Company's common stock			4,800,000
Exercise price			$0.02
Stock option exercisable period			10 years
Fair value of the option vested			90,431
Dividend yield			0.00%
Volatility			163.63%
Risk free rate			2.75%
Officer and Employee [Member]
Stock Options and Warrants (Textual)
Options to purchase the Company's common stock				700,000	4,848,487	2,400,000	4,890,000
Exercise price				$0.02	$0.03	$0.02	$0.02
Range of Exercise Prices, Minimum							$0.03
Range of Exercise Prices, Maximum							$0.21
Interest expense							1,630
Stock option vesting right percentage				25.00%
Stock option vesting period				10 years	4 years
Stock option exercisable period					10 years
Fair value of the option vested				12,739	130,135	37,823
Dividend yield				0.00%	0.00%	0.00%
Volatility				152.87%	161.36%	150.98%
Risk free rate				2.36%	2.66%	2.78%
Officer and Employee One [Member]
Stock Options and Warrants (Textual)
Options to purchase the Company's common stock								15,000,000
Exercise price								$0.03
Stock option vesting right percentage								25.00%
Stock option vesting period								3 years
Stock option exercisable period								10 years
Fair value of the option vested								391,798
Dividend yield								0.00%
Volatility								168.62%
Risk free rate								2.52%
Employee [Member]
Stock Options and Warrants (Textual)
Options to purchase the Company's common stock									15,000,000
Exercise price									$0.02
Interest expense									25,599
Stock option vesting period									4 years
Fair value of the option vested									245,749
Dividend yield									0.00%
Volatility									153.27%
Risk free rate									2.74%
Board of Directors [Member]
Stock Options and Warrants (Textual)
Options to purchase the Company's common stock				2,800,000
Exercise price				$0.02
Stock option vesting period				10 years
Fair value of the option vested				54,957
Dividend yield				0.00%
Volatility				152.87%
Risk free rate				2.36%
Warrant [Member]
Stock Options and Warrants (Textual)
Warrants issued	8,000,000			13,063,530
Interest expense	103,238
Dividend yield				0.00%
Volatility				152.87%
Risk free rate				0.96%
Share based compensation shares authorized	41,582,469	50,000,000
Fair value of vested warrants				148,517
Warrant vesting period description	Vesting from June 8, 2014 through March 10, 2016.
Warrants exercise price	$0.02
Warrant vesting period	4 years			3 years
Warrant [Member] \| Intellectual Property [Member]
Stock Options and Warrants (Textual)
Warrants issued	4,000,000
Fair value of vested warrants	32,878
Warrant vesting period description	Vesting from July 6, 2014 through April 6, 2017.
Warrants exercise price	$0.05
Warrant vesting period	4 years
Warrant One [Member]
Stock Options and Warrants (Textual)
Warrants issued	4,000,000
Interest expense	$54,146
Warrants exercise price	$0.02
Warrant vesting period	4 years

Commiments_and_Contingencies_D

Commiments and Contingencies (Details) (USD $)	Dec. 31, 2014
Commitments and Contingencies [Abstract]
2015	$86,382
2016	43,830
Total	$130,212

Commiments_and_Contingencies_D1

Commiments and Contingencies (Details Textual) (USD $)	1 Months Ended	12 Months Ended		0 Months Ended		1 Months Ended
Commiments and Contingencies (Details Textual) (USD $)	Jun. 30, 2000	Dec. 31, 2014	Dec. 31, 2013	Jul. 28, 2014	Nov. 03, 2014	Nov. 20, 2013
Commitments and Contingencies (Textual)
Percentage of ownership in new entity		33.00%
Interest expense		$1,639,571	$1,437,883
Patent expiration period	2015
Accrued expenses		2,122,130
Rent expense		128,136	123,216
Chief Executive Officer [Member]
Commitments and Contingencies (Textual)
Salary to Officer				525,000
Bonus to Officers				500,000
Options to acquire company's common stock				10,000,000
Stock option exercisable period				10 years
Stock option vesting period				4 years
Chief Executive Officer [Member] \| Maximum [Member]
Commitments and Contingencies (Textual)
Bonus to Officers				500,000
Chief Executive Officer [Member] \| Minimum [Member]
Commitments and Contingencies (Textual)
Bonus to Officers				150,000
Chief Scientific Officer [Member]
Commitments and Contingencies (Textual)
Salary to Officer				250,000
Bonus to Officers				300,000
Options to acquire company's common stock				5,000,000
Stock option exercisable period				10 years
Stock option vesting period				4 years
Chief Scientific Officer [Member] \| Maximum [Member]
Commitments and Contingencies (Textual)
Bonus to Officers				300,000
Chief Scientific Officer [Member] \| Minimum [Member]
Commitments and Contingencies (Textual)
Bonus to Officers				100,000
Warrant [Member]
Commitments and Contingencies (Textual)
Warrants issued		8,000,000			13,063,530
Fair value of vested warrants					148,517
Warrants exercise price		$0.02
Interest expense		103,238
Warrants vesting description		2,000,000 warrants vesting 90 days from the effective date, 2,000,000 vesting on each anniversary date for three years.
Warrant exercise period		3 years
Warrant expected to vest in future period		2,000,000
Warrant [Member] \| Consulting Agreements [Member]
Commitments and Contingencies (Textual)
Warrants exercise price						$0.01
Warrant exercise period						10 years
Accrued expenses		71,504	32,424
Fess received by Cassel Salpeter & Co						CSC will receive a one-time $25,000 fee, $5,000 monthly fees.
Common stock purchase warrants						5,207,630
Warrant [Member] \| Revenue Share Arrangement [Member]
Commitments and Contingencies (Textual)
Warrants issued		12,000,000
Interest expense		$54,146
Warrant exercise period		4 years
Common stock purchase warrants		4,000,000

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
Income Taxes (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Summary of federal statutory corporate tax rate and actual income tax expense
Income taxes using U.S. federal statutory rate	($766,194)	($1,068,708)
State income taxes, net of federal benefit	-90,051	-108,788
Stock Option Expirations	66,043	78,864
Net Operating Loss adjustments	-144,824	-20,008
Nontaxable Gain on Derivative Instrument	933,477	-9,921
Change in Valuation Allowance	1,549	1,127,875
Other		686
Income taxes (benefit)

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Stock Based Compensation	$4,794,777	$4,465,854
Net Operating Losses	36,117,831	35,429,429
Other	41,469	125,317
Total deferred tax assets	40,954,077	40,020,600
Deferred tax liabilities:
Total deferred tax liabilities
Valuation allowance	40,954,077	40,020,600
Net deferred tax assets

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Taxes (Textual)
Operating loss carryforwards, expiration dates	Expire at various dates from 2019 through 2034.
Annual limit of corporation to reduce its tax liability	An annual limit on the ability of a corporation that undergoes a greater than 50% ownership change to use its net operating loss carry forwards to reduce its tax liability.
Description of equity method ownership change	If in the future the Company issues common stock or additional equity instruments convertible in common shares which result in an ownership change exceeding the 50% limitation threshold imposed by section 382 of the Code, the Company's net operating loss carryforwards may be significantly limited as to the amount of use in a particular years.
U.S. Federal [Member]
Income Taxes (Textual)
Operating loss carryforwards, net	95.8	$94.20
State Jurisdiction [Member]
Income Taxes (Textual)
Operating loss carryforwards, net	95.8	$94.20

Fair_Value_Measurement_Details

Fair Value Measurement (Details) (USD $)	12 Months Ended
Fair Value Measurement (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Total (gains) losses
Balance	$964,090
Net (Loss) Gain for the period included in earnings relating to the liabilities held at December 31, 2014	425,953	29,179
Excess Share Derivative [Member]
Summary of changes in fair value of the Company's Level 3 financial liabilities
Beginning Balance		390,048
Total (gains) losses
Initial fair value of debt derivative at note issuance
Initial fair value of derivative relating to reset warrants
Mark-to-market		84,906
Transfers out of Level 3 upon increase in authorized shares		-474,954
Transfers out of Level 3 upon conversion and settlement of notes
Transfers out of Level 3 upon conversion or payoff of notes payable
Balance
Net (Loss) Gain for the period included in earnings relating to the liabilities held at December 31, 2014
Warrant [Member]
Summary of changes in fair value of the Company's Level 3 financial liabilities
Beginning Balance	146,855	221,179
Total (gains) losses
Initial fair value of debt derivative at note issuance
Initial fair value of derivative relating to reset warrants
Mark-to-market	3,065	-74,324
Transfers out of Level 3 upon increase in authorized shares
Transfers out of Level 3 upon conversion and settlement of notes
Transfers out of Level 3 upon conversion or payoff of notes payable
Balance	149,920	146,855
Net (Loss) Gain for the period included in earnings relating to the liabilities held at December 31, 2014	-3,065
Derivative [Member]
Summary of changes in fair value of the Company's Level 3 financial liabilities
Beginning Balance	256,956
Total (gains) losses
Initial fair value of debt derivative at note issuance	1,443,708	673,219
Initial fair value of derivative relating to reset warrants
Mark-to-market	-429,018	-39,761
Transfers out of Level 3 upon increase in authorized shares
Transfers out of Level 3 upon conversion and settlement of notes		-376,502
Transfers out of Level 3 upon conversion or payoff of notes payable	-680,295
Balance	591,351	256,956
Net (Loss) Gain for the period included in earnings relating to the liabilities held at December 31, 2014	$429,018

Fair_Value_Measurement_Details1

Fair Value Measurement (Details Textual) (USD $)	12 Months Ended
Fair Value Measurement (Details Textual) (USD $)	Dec. 31, 2014
Fair Value Measurement (Textual)
Derivative liability	$964,090
Percentage of stock price increase	5.00%
Change in pricing inputs	A 10 percent change in pricing inputs and changes in volatilities and correlation factors would result in less than a $129,253 change in our Level 3 fair value.

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	0 Months Ended	12 Months Ended		0 Months Ended	1 Months Ended			0 Months Ended	1 Months Ended
Subsequent Events (Details) (USD $)	Oct. 03, 2014	Dec. 31, 2014	Dec. 31, 2013	Nov. 03, 2014	Mar. 31, 2015	Feb. 28, 2015	Jan. 31, 2015	Jan. 07, 2015	Jan. 28, 2015	Feb. 19, 2015
Subsequent Event [Line Items]
Common shares issued in conversion of debt		48,584,542	57,967,906
Accrued interest	$12,705	$12,635	$598,125
Common stock issued from equity drawdown	514,886	274,681
Issuance of common stock, Shares		42,066,606
Issuance of common stock		479,625	865,000
Board of Directors [Member]
Subsequent Event [Line Items]
Options granted to purchase common stock				2,800,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock issued for services, Shares							4,783,568
Common shares issued in conversion of debt					6,185,432	20,219,367	14,299,567
Amount issued in conversion of debt					25,000	132,500	49,500
Accrued interest					1,226	2,520	2,981
Common stock issued					635,357	16,556,976	2,096,450
Common stock issued from equity drawdown						135,645	16,118
Issuance of common stock, Shares						1,443,656
Issuance of common stock						16,270
Issuance of warrants for common stock						1,443,656
Warrants Term						5 years
Warrant exercise price						$0.01
Subsequent Event [Member] \| KBM Worldwide, Inc [Member]
Subsequent Event [Line Items]
Convertible Debt								38,000
Interest rate								8.00%
Debt instrument, Maturity date								9-Oct-15
Note conversion, description								The Note is convertible into common stock, at KBM’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.
Subsequent Event [Member] \| Fourth Man, LLC [Member]
Subsequent Event [Line Items]
Convertible Debt									25,000
Interest rate									9.50%
Debt instrument, Maturity date									27-Jan-16
Note conversion, description									The Note is convertible into common stock, at Asher’s option, at a 47% discount to the lowest daily closing trading price of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 150%, interest and any other amounts.
Subsequent Event [Member] \| Vis Vires Group [Member]
Subsequent Event [Line Items]
Convertible Debt										$38,000
Interest rate										8.00%
Debt instrument, Maturity date										23-Nov-15
Note conversion, description										The Note is convertible into common stock, at VIS’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.
Subsequent Event [Member] \| Board of Directors [Member]
Subsequent Event [Line Items]
Options granted to purchase common stock						7,000,000
Excercise price of options						$0.01
Expiration of options						10 years